var title_f35_57_36752="Mometasone: Pediatric drug information";
var content_f35_57_36752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mometasone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/20/42307?source=see_link\">",
"       Mometasone (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/6/28773?source=see_link\">",
"       Mometasone (oral inhalation): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/8/13444?source=see_link\">",
"       Mometasone (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12573 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36752=[""].join("\n");
var outline_f35_57_36752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/20/42307?source=related_link\">",
"      Mometasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/6/28773?source=related_link\">",
"      Mometasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/8/13444?source=related_link\">",
"      Mometasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_57_36753="Optic disc Frisen grade 2";
var content_f35_57_36753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade II showing the halo of disc edema is circumferential.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36753=[""].join("\n");
var outline_f35_57_36753=null;
var title_f35_57_36754="MRI spinal hemangioblastoma";
var content_f35_57_36754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Spinal cord hemangioblastoma: MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Left panel) Gadolinium-enhanced, T-1 weighted sagittal MRI image of an enhancing hemangioblastoma located on the dorsal surface of the spinal cord at the level of T8.",
"    <br>",
"     (Right panel) Axial image of the same lesion.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Eric T Wong, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36754=[""].join("\n");
var outline_f35_57_36754=null;
var title_f35_57_36755="Palonosetron: Patient drug information";
var content_f35_57_36755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Palonosetron: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     see \"Palonosetron: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26916?source=see_link\">",
"     see \"Palonosetron: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14877561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aloxi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691476",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop upset stomach and throwing up from chemo.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691477",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop upset stomach and throwing up from surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to palonosetron or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low potassium or magnesium level, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A faster, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11422 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36755=[""].join("\n");
var outline_f35_57_36755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14877561\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022384\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022386\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022385\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022390\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022391\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022393\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022388\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022395\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=related_link\">",
"      Palonosetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26916?source=related_link\">",
"      Palonosetron: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_57_36756="Probenecid: Patient drug information";
var content_f35_57_36756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Probenecid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     see \"Probenecid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11382?source=see_link\">",
"     see \"Probenecid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benuryl&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop gouty arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691453",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop gout attacks. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692140",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with some antibiotics to help fight the infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a child younger than 2 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to probenecid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a blood disease or kidney stones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ulcer disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11841 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36756=[""].join("\n");
var outline_f35_57_36756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213409\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022192\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022194\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022193\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022198\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022199\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022201\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022196\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022197\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022202\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022203\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=related_link\">",
"      Probenecid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11382?source=related_link\">",
"      Probenecid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_57_36757="Hepatobiliary cystadenoma";
var content_f35_57_36757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatobiliary cystadenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Ultrasound shows a large cystic lesion with septations and slightly irregular wall. Panel B: CT scan demonstrates the same cyst occupying most of the left hepatic lobe. Panel C: Histologic appearance: Low power magnification showing the wall of the cyst composed of a layer of loose vascular, spindle cell stroma lined by tall columnar epithelium. Note polypoid projections (hematoxylin and eosin, original magnification: x 400). Panel D: Closer view demonstrates the layer of simple columnar epithelium with focal areas of pseudostratification. No cellular atypia or pleomorphism is noted (hematoxylin and eosin, original magnification: x 2000).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Regev, A, Reddy, KR, Berho, M, et al. Large cystic lesions of the liver in adults: A 15-year experience in a tertiary center. J Am Coll Surg 2001; 193:36. Copyright &copy; 2001 American College of Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36757=[""].join("\n");
var outline_f35_57_36757=null;
var title_f35_57_36758="Bullous pemphigoid tense bullae";
var content_f35_57_36758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tense blisters in bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    &nbsp; Multiple tense bullae on inflamed skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36758=[""].join("\n");
var outline_f35_57_36758=null;
var title_f35_57_36759="Amanita smithiana mushroom poisoning";
var content_f35_57_36759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amanita smithiana mushroom poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36759/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36759/contributors\">",
"     Patrick West, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36759/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36759/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/57/36759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24102654\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amanita smithiana is a mushroom found primarily on the West Coast of North America. Toxic ingestion causes a syndrome of acute gastroenteritis within minutes to hours of consumption followed by delayed onset renal failure within one week. Although uncommon, Amanita smithiana poisoning has increased in frequency over the last two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/1\">",
"     1",
"    </a>",
"    ]. It represents the only known mushroom poisoning syndrome where ingestion of a single type of mushroom can have immediate acute effects that are followed by serious delayed toxicity (",
"    <a class=\"graphic graphic_table graphicRef77875 \" href=\"mobipreview.htm?11/28/11727\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, toxicity, clinical manifestations, and management of Amanita smithiana mushroom poisoning. Evaluation and management of other poisonous mushrooms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42615?source=see_link\">",
"     \"Management of mushroom poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102661\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amanita smithiana is a white mushroom that grows in pine forests on the West coast of North America, primarily from British Columbia to Northern California, though they have been observed as far south as the mountains of New Mexico [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2\">",
"     2",
"    </a>",
"    ]. Ingestion has also been reported in Southeast Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/3\">",
"     3",
"    </a>",
"    ]. A. smithiana mushrooms grow in the autumn until the time of the first frost, typically growing near dead or rotting wood.",
"   </p>",
"   <p>",
"    Toxicity from Amanita smithiana was first described in 1964, although its toxic effects were misattributed to A. phalloides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/4\">",
"     4",
"    </a>",
"    ]. Following the initial report, almost 30 years passed without a documented case. In the 1990s, A. smithiana mushroom poisoning became more commonly described in association with increasing culinary popularity and economic value of the matsutake or pine mushroom (Tricholoma magnivelare), which has a similar habitat and appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. Publication of the book &ldquo;Matsutake Mushroom: White gold rush of the 1990s&rdquo; in 1997 coincided with the largest spike in reports of these ingestions in 1997 and 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/8\">",
"     8",
"    </a>",
"    ]. In all cases of poisoning reported to date, A. smithiana have been ingested by individuals collecting and preparing the look-alike matsutake or pine mushroom (",
"    <a class=\"graphic graphic_picture graphicRef69427 \" href=\"mobipreview.htm?10/37/10840\">",
"     picture 1",
"    </a>",
"    ) for personal culinary use.",
"   </p>",
"   <p>",
"    Matsutake mushrooms are also extremely desirable for commercial culinary use. Matsutakes have been gathered in regions where A. smithiana is native and sold to restaurants in areas where A. smithiana is not, making poisoning possible outside of the West coast of North America or Southeast Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children are also at risk from unintentional sampling of the A. smithiana mushroom although exploratory mushroom ingestions in children typically consist of one bite and serious poisoning in this setting is rare. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21617122#H21617122\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A recent case series suggested that other Amanita species found in Europe (eg, A. boudieri and A. echinocephala) may produce toxicity similar to that seen with A. Smithiana [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/9\">",
"     9",
"    </a>",
"    ]. Although these mushrooms were not found to contain allenic norleucine, the purported toxin in A. smithiana, they did have a substance identified by thin layer chromatography that was also found in a toxic extract from A. smithiana.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5480951\">",
"    <span class=\"h1\">",
"     MUSHROOM APPEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mushroom identification is usually not readily available during the acute phase of care, and most mushrooms causing toxicity are never correctly identified. However, if possible, determination of the specific type of mushroom ingested can be helpful for treatment recommendations and prognosis. Consultation with a medical toxicologist and professional mycologist is strongly advised when attempting mushroom identification (US regional poison control center: 1-800-222-1222 or access the World Health Organization's list of international poison centers [",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Amanita smithiana is usually white, though color can vary (brown, gray, or yellow) based upon weather during growth. It has a universal veil on the cap. The cap may range from 5 to 17 cm across. The stipe (or stem) may be from 6 to over 16 cm (",
"    <a class=\"graphic graphic_picture graphicRef69427 \" href=\"mobipreview.htm?10/37/10840\">",
"     picture 1",
"    </a>",
"    ). The stipe does not have the volva (bulbous cup at the base of the stem) seen on many other Amanita species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102682\">",
"    <span class=\"h1\">",
"     PHARMACOTOXICOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amanita smithiana contains the toxin allenic norleucine (amino-hexadienoic acid) which is present in Amanita smithiana mushrooms and causes renal toxicity in cell culture and animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Both raw and cooked A. smithiana appear to cause toxicity, suggesting allenic norleucine is a heat-stable toxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allenic norleucine is not related to amatoxin found in other more commonly ingested and phylogenetically related Amanita mushrooms such as Amanita phalloides, A. virosa, A. verna, or A. bisporigera.",
"   </p>",
"   <p>",
"    Several observations indicate that allenic norleucine rather than orelline or other toxins cause the renal toxicity seen in Amanita smithiana poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allenic norleucine and A. smithiana extract caused identical renal tubular epithelial cell necrosis within 12 hours in a cell culture model.",
"     </li>",
"     <li>",
"      Renal tubular epithelial cells incubated with orelline (the toxin from the largest group of delayed renal toxicity mushrooms) displayed a different pattern of toxicity and slower onset of cell death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21620032#H21620032\">",
"       \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Delayed renal failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The C-terminus of the allenic norleucine is hypothesized to confer the toxicity of the molecule, as non-allenic norleucine does not cause renal toxicity.",
"     </li>",
"     <li>",
"      When renal tubular epithelial cells are incubated with allenic norleucine and glutathione, there was no change in the observed toxicity, suggesting that N-acetyl cysteine is unlikely to affect the clinical course of A. smithiana ingestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Human pathologic findings have been described in one patient who underwent renal biopsy 43 days after suspected Amanita smithiana mushroom ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/4\">",
"     4",
"    </a>",
"    ]. Light microscopy showed diffuse interstitial fibrosis without inflammatory changes. Renal tubules were dilated and contained cellular debris. Electron microscopy showed involvement of both the proximal and distal tubules. Many large vesicles were present, and mitochondrial membranes were disrupted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5481816\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected mushroom poisoning, the clinician should provide prompt support of airway, breathing, and circulation, as needed. A regional poison control center should be contacted to discuss likely mushroom species ingested based upon clinical findings, identification of any mushrooms available for analysis, and treatment of specific toxic effects. Most poison control centers maintain active call lists of mycologists who are knowledgeable concerning local prevalence of mushroom genera and species and can assist in mushroom identification. To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The table provides a description of the various mushroom poisoning syndromes (",
"    <a class=\"graphic graphic_table graphicRef77875 \" href=\"mobipreview.htm?11/28/11727\">",
"     table 1",
"    </a>",
"    ). A discussion of the clinical recognition and management of poisoning by other mushroom species is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42615?source=see_link\">",
"     \"Management of mushroom poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of Amanita smithiana mushroom poisoning relies upon the recognition of the clinical presentation. The diagnosis is strengthened by specific mushroom identification if available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102689\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amanita smithiana mushrooms cause symptoms 20 minutes to 12 hours after ingestion with the typical onset occurring at five to six hours. Initial clinical findings include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Abdominal cramping",
"     </li>",
"     <li>",
"      Diarrhea (less common)",
"     </li>",
"     <li>",
"      Increased urine output (less common)",
"     </li>",
"     <li>",
"      Diaphoresis (less common)",
"     </li>",
"     <li>",
"      Dizziness (less common)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nausea and vomiting typically gives way to an asymptomatic period after 6 to 24 hours of symptoms although persistent nausea and vomiting has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. There are no reports of major abnormalities of airway, breathing, or circulation during this initial phase of A. smithiana toxicity.",
"   </p>",
"   <p>",
"    Three to six days after A. smithiana mushroom consumption, patients begin to have symptoms of renal failure, most notably oliguria and anuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. A large percentage of patients seek initial medical care during this &ldquo;delayed&rdquo; time frame (three to six days), as the initial symptoms are self-limited. Decreased urine output is the primary presenting complaint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. Renal failure typically ensues and will gradually resolve over several weeks to months with proper supportive care. Other than renal failure, patients have few clinical effects in other organ systems during the recovery period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102696\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clinically available test for allenic norleucine. Specific testing to identify mushrooms and their toxins is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute testing in patients with mushroom exposures is guided by the clinical presentation. Asymptomatic children with ingestions that are unlikely to be toxic may be observed without any testing. Patients with ingestion of potentially toxic mushrooms, including Amanita smithiana should undergo baseline assessment of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum electrolytes, calcium, and phosphate",
"     </li>",
"     <li>",
"      Blood urea nitrogen and serum creatinine",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Serum creatinine",
"     </li>",
"     <li>",
"      Liver studies (eg, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total protein, albumin, total and direct bilirubin)",
"     </li>",
"     <li>",
"      Prothrombin time (PT), partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      Complete blood count with platelets",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If acute renal failure is present, additional studies to obtain include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urine sodium concentration",
"     </li>",
"     <li>",
"      Urine creatinine concentration",
"     </li>",
"     <li>",
"      Renal ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal insufficiency is typically",
"    <strong>",
"     not",
"    </strong>",
"    evident on laboratory evaluation immediately after ingestion of Amanita smithiana mushrooms. The creatinine begins to rise within 24 hours of ingestion. The renal failure from A. smithiana will gradually worsen over the course of a week. Renal function, acid-base status, and serum electrolytes should be monitored over the next several weeks to determine if dialysis is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to renal failure from A. smithiana, orellanine-containing mushrooms, such as Cortinarius species, Mycena pura, and Omphalatus orarius, display renal toxicity in a more delayed fashion with evidence of renal insufficiency typically presenting later (up to 20 days after consumption) although large ingestion may cause symptoms as early as three days after orellanine-containing mushroom consumption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21620032#H21620032\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Delayed renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several cases of A. smithiana mushroom poisoning have demonstrated a small initial elevations in AST and ALT up to 300 to 400",
"    <span class=\"nowrap\">",
"     Units/L",
"    </span>",
"    (approximately six times the normal upper limit of normal); these appear to resolve by day four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. Lactate dehydrogenase (LDH) has also been noted to be elevated in several of the described patients. In contrast, after A. phalloides poisoning, hepatic damage will be the primary feature of ingestion, and liver function tests will continue to rise to very high levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5483596\">",
"    <span class=\"h2\">",
"     Mushroom identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, samples of all ingested mushrooms should be obtained. Whole mushrooms are preferred, but identification can be made on parts of the mushroom, especially the cap. Storage is facilitated by wrapping the mushrooms in wax paper, placing it in a paper bag, and refrigerating the sample. Storage in plastic bags should be avoided. Unfortunately, patients often ingest multiple mushrooms and have cooked or otherwise damaged the fungi they have ingested, making direct identification difficult if not impossible. Mushroom identification is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102718\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of mushroom poisoning typically relies upon clinical manifestations and recognition of specific mushroom poisoning syndromes (",
"    <a class=\"graphic graphic_table graphicRef77875 \" href=\"mobipreview.htm?11/28/11727\">",
"     table 1",
"    </a>",
"    ). Patients with Amanita smithiana mushroom poisoning may have clinical or laboratory findings of hepatotoxicity and kidney disease that overlap with the poisoning syndromes caused by amatoxin-containing and orellanine-containing mushrooms.",
"   </p>",
"   <p>",
"    When compared with victims of amatoxin-containing mushroom poisoning, patients with A. smithiana ingestion may have small elevations in liver aminotransferases up to 300 to 400",
"    <span class=\"nowrap\">",
"     Units/L",
"    </span>",
"    but will usually not have values over 1000",
"    <span class=\"nowrap\">",
"     Units/L.",
"    </span>",
"    The liver aminotransferase elevations associated with A. smithiana poisoning will resolve by four days. In contrast, patients with amatoxin-containing mushroom poisoning typically have continued elevation beyond four days after mushroom consumption. In circumstances where A. smithiana ingestion cannot be clinically differentiated from amatoxin-containing mushroom poisoning, the clinician should initiate specific therapy for amatoxin-containing mushroom toxicity (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link&amp;anchor=H26667347#H26667347\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link&amp;anchor=H26667361#H26667361\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with orellanine-containing mushroom poisoning typically have a more delayed onset of symptoms than victims of A. smithiana poisoning; gastrointestinal symptoms occur up to four days after mushroom consumption and renal failure typically occurs more than one week postingestion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21620032#H21620032\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Delayed renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other mushroom poisoning syndromes are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21619983#H21619983\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom poisoning syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102710\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the care of children and adults with Amanita smithiana mushroom poisoning are derived from case series and reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. Treatment focuses on the prevention of toxin absorption and supportive care. There is no specific antidote.",
"   </p>",
"   <p>",
"    In circumstances where A. smithiana ingestion cannot be clinically differentiated from amatoxin-containing mushroom poisoning, the clinician should initiate specific therapy for amatoxin-containing mushroom toxicity (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link&amp;anchor=H26667347#H26667347\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link&amp;anchor=H26667361#H26667361\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5483156\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with A. smithiana mushroom poisoning frequently require management of vomiting, diarrhea, hypovolemia, and acute renal failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vomiting may be treated with an antiemetic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously) to facilitate administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      soon after ingestion. Vomiting that is induced more than 60 minutes after toxin ingestion does not significantly reduce absorption. Thus, it is presumed that inhibition of spontaneous vomiting beyond that time frame will not increase toxin absorption and symptomatic treatment of vomiting is also appropriate. (See",
"      <a class=\"local\" href=\"#H24102726\">",
"       'GI decontamination'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H3#H3\">",
"       \"Decontamination of poisoned children\", section on 'Syrup of ipecac'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fluid repletion should be given based upon clinical assessment of losses and evidence of dehydration. Patients with signs of shock should receive prompt fluid resuscitation (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"mobipreview.htm?41/12/42178\">",
"       algorithm 1",
"      </a>",
"      ). However, care should be taken",
"      <strong>",
"       not",
"      </strong>",
"      to overhydrate patients with oliguric or anuric renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"       \"Initial management of shock in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"       \"Maintenance and replacement fluid therapy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"       \"Treatment of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis is frequently, though not always, required in cases of A. smithiana ingestion for replacement of renal function. The effect of dialysis on toxin elimination has not been evaluated. All cases of A. smithiana induced renal failure have been self-limited. Supportive dialysis has typically been necessary for between two to five weeks, though in one case it was required for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. Dialysis typically begins four to seven days after mushroom ingestion and has been performed in the inpatient and outpatient settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The major complications of renal failure include volume overload, hyperkalemia, metabolic acidosis, hypocalcemia, and hyperphosphatemia. The initial assessment therefore includes the careful evaluation of volume status and measurement of serum electrolytes, particularly potassium and bicarbonate, and evaluation of a complete blood count and serum phosphate, calcium, albumin and uric acid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H507571#H507571\">",
"       \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Delayed gastroenteritis and renal failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21620032#H21620032\">",
"       \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Delayed renal failure'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Accepted indications for dialysis in patients with renal failure generally include (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fluid overload that is refractory to diuretics",
"     </li>",
"     <li>",
"      Hyperkalemia (serum potassium concentration &gt;6.5",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      or rapidly rising serum potassium, as can occur in rhabdomyolysis",
"     </li>",
"     <li>",
"      Metabolic acidosis (arterial pH less than 7.10) in patients in with volume overload, which will be made worse by the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      , or with lactic acidosis, which is generally not treated with bicarbonate.",
"     </li>",
"     <li>",
"      Signs of uremia, such as pericarditis, neuropathy, or an otherwise unexplained decline in mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102726\">",
"    <span class=\"h2\">",
"     GI decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that alert patients who ingest Amanita smithiana mushrooms and present within one hour of ingestion receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    maximum dose: 50 grams). The recommendation for AC administration soon after A. smithiana mushroom consumption derives from indirect evidence of benefit in volunteers who ingested other toxins, animal studies, and evidence of benefit following ingestions of other mushrooms. Mushrooms, like most complex xenobiotics, bind well to activated charcoal. Because diarrhea is a common occurrence after A. smithiana poisoning, the combination of a cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ) and AC should avoided. The greatest benefit occurs if AC is given within one hour of ingestion. However, AC is unlikely to be of benefit in most instances of A. smithiana poisoning because patients do not typically seek medical attention until days after mushroom consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H27#H27\">",
"     \"Decontamination of poisoned children\", section on 'Cathartics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H10032467#H10032467\">",
"     \"Decontamination of poisoned children\", section on 'Activated charcoal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H10032558#H10032558\">",
"     \"Decontamination of poisoned children\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    We recommend that patients who ingest potentially toxic mushrooms",
"    <strong>",
"     not",
"    </strong>",
"    undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department. This recommendation is based upon randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. Syrup of ipecac administered in locations far from definite medical care and soon after pediatric ingestion may prevent toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36759/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link&amp;anchor=H3#H3\">",
"     \"Decontamination of poisoned children\", section on 'Syrup of ipecac'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"     \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5483807\">",
"    <span class=\"h2\">",
"     Elimination enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;No methods of elimination enhancement, including multiple dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , hemoperfusion, or hemodialysis have been shown to reduce the concentration or effect of allenic norleucine, the primary toxin contained in Amanita smithiana.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5483826\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mushroom identification is often not available. Thus, disposition after mushroom poisoning is typically guided by clinical findings. Consultation with a regional or international poison control center is advised to assist with disposition decisions. (See",
"    <a class=\"local\" href=\"#H5483840\">",
"     'Additional resources'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42615?source=see_link&amp;anchor=H1458107#H1458107\">",
"     \"Management of mushroom poisoning\", section on 'Disposition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following patients warrant hospital admission:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with delayed symptoms more than six hours after mushroom ingestion",
"     </li>",
"     <li>",
"      Patients with early symptoms less than three hours after mushroom ingestion who remain symptomatic beyond six hours despite supportive care or who ingested more than one type of mushroom",
"     </li>",
"     <li>",
"      Patients with acute renal failure",
"     </li>",
"     <li>",
"      Asymptomatic patients after a known ingestion of Amanita smithiana in whom outpatient follow-up cannot be assured",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asymptomatic patients after a known ingestion of Amanita smithiana may be followed as outpatients as long as monitoring of renal function starting at three days and occurring daily up to seven days can be assured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5483840\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct consultation with knowledgeable poison specialists, medical toxicologists, and mycologists is available through regional poison control centers. In the United States, call 1-800-222-1222 or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ). Clinicians should",
"    <strong>",
"     not",
"    </strong>",
"    use the internet for identification of toxic mushroom species without expert consultation.",
"   </p>",
"   <p>",
"    The toxicology section of the North American Mycological Association website provides lists of emergency identification volunteers available in North America, an overview of mushroom poisoning syndromes with pictures, and archived toxicology reports that describe specifics of poisoning cases in which NAMA mycologists provided assistance (",
"    <a class=\"external\" href=\"file://www.namyco.org/toxicology/index.html\">",
"     www.namyco.org/toxicology/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24102788\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When mushroom poisoning is suspected, a regional poison control center should be contacted to discuss likely mushroom species ingested based upon clinical findings, to assist with identification of any mushrooms available for analysis, and to provide treatment recommendations. To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5483840\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amanita smithiana is a large white mushroom (",
"      <a class=\"graphic graphic_picture graphicRef69427 \" href=\"mobipreview.htm?10/37/10840\">",
"       picture 1",
"      </a>",
"      ) that grows in the pine forests of the West Coast of North American and in Southeast Asia. It is typically ingested unintentionally by individuals seeking the edible pine (or matsutake) mushroom (Tricholoma magnivelare) (",
"      <a class=\"graphic graphic_picture graphicRef69427 \" href=\"mobipreview.htm?10/37/10840\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24102661\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of Amanita smithiana mushroom poisoning consists of self-limited acute gastroenteritis starting 20 minutes to 12 hours after consumption with the typical onset occurring at five to six hours. Acute renal failure becomes clinically apparent three to six days postingestion. (See",
"      <a class=\"local\" href=\"#H24102689\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of Amanita smithiana mushroom poisoning relies upon the recognition of the clinical presentation (",
"      <a class=\"graphic graphic_table graphicRef77875 \" href=\"mobipreview.htm?11/28/11727\">",
"       table 1",
"      </a>",
"      ). The diagnosis is strengthened by specific mushroom identification if available. (See",
"      <a class=\"local\" href=\"#H5483596\">",
"       'Mushroom identification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=see_link&amp;anchor=H21617164#H21617164\">",
"       \"Clinical manifestations and evaluation of mushroom poisoning\", section on 'Mushroom identification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In circumstances where A. smithiana ingestion cannot be clinically differentiated from amatoxin-containing mushroom poisoning, the clinician should initiate specific therapy for amatoxin-containing mushroom toxicity (See",
"      <a class=\"local\" href=\"#H24102718\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link&amp;anchor=H26667347#H26667347\">",
"       \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\", section on 'Evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=see_link&amp;anchor=H26667361#H26667361\">",
"       \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of Amanita smithiana mushroom poisoning focuses on the prevention of toxin absorption and supportive care. There is no specific antidote. (See",
"      <a class=\"local\" href=\"#H24102710\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that alert patients who ingest Amanita smithiana mushrooms and present within one hour of ingestion receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       g/kg,",
"      </span>",
"      maximum dose: 50 grams) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24102726\">",
"       'GI decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who ingest potentially toxic mushrooms",
"      <strong>",
"       not",
"      </strong>",
"      undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24102726\">",
"       'GI decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Amanita smithiana mushroom poisoning frequently require management of vomiting, diarrhea, hypovolemia, and acute renal failure. (See",
"      <a class=\"local\" href=\"#H5483156\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following patients warrant hospital admission (see",
"      <a class=\"local\" href=\"#H5483826\">",
"       'Disposition'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with delayed symptoms more than six hours after mushroom ingestion",
"     </li>",
"     <li>",
"      Patients with early symptoms less than three hours after mushroom ingestion who remain symptomatic beyond six hours despite supportive care or who ingested more than one type of mushroom",
"     </li>",
"     <li>",
"      Patients with acute renal failure",
"     </li>",
"     <li>",
"      Asymptomatic patients after a known ingestion of Amanita smithiana in whom outpatient follow-up cannot be assured",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amanita smithiana induced renal failure is self-limited, and dialysis is often required. Recovery to baseline renal function typically occurs within two to five weeks, but may be delayed up to six months. (See",
"      <a class=\"local\" href=\"#H5483156\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/1\">",
"      Broussard CN, Aggarwal A, Lacey SR, et al. Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol 2001; 96:3195.",
"     </a>",
"    </li>",
"    <li>",
"     Tulloss RE, Lindgren JE. Amanita smithiana - taxonomy, distribution, and poisonings. Mycotaxon 1992; 45:373. file://www.cybertruffle.org.uk/cyberliber/index.htm (Accessed on October 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/3\">",
"      Yang WS, Lin CH, Huang JW, Fang CC. Acute renal failure caused by mushroom poisoning. J Formos Med Assoc 2006; 105:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/4\">",
"      Myler, R, Lee, J, Hopper, J. Renal tubular necrosis caused by mushroom poisoning. Ann Intern Med 1964; 114:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/5\">",
"      Leathem AM, Purssell RA, Chan VR, Kroeger PD. Renal failure caused by mushroom poisoning. J Toxicol Clin Toxicol 1997; 35:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/6\">",
"      Warden CR, Benjamin DR. Acute renal failure associated with suspected Amanita smithiana mushroom ingestions: a case series. Acad Emerg Med 1998; 5:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/7\">",
"      West PL, Lindgren J, Horowitz BZ. Amanita smithiana mushroom ingestion: a case of delayed renal failure and literature review. J Med Toxicol 2009; 5:32.",
"     </a>",
"    </li>",
"    <li>",
"     Guin, J. Matsutake Mushroom: The White Gold Rush of the 1990s, A Guide and Journal, Naturegraph Publishers, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/9\">",
"      Kirchmair M, Carrilho P, Pfab R, et al. Amanita poisonings resulting in acute, reversible renal failure: new cases, new toxic Amanita mushrooms. Nephrol Dial Transplant 2012; 27:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/10\">",
"      Chilton WS, Ott J. Toxic metabolites of Amanita pantherina, A. cothurnata, A. muscaria and other Amanita species. Lloydia 1976; 39:150.",
"     </a>",
"    </li>",
"    <li>",
"     Pelizzari V, Feifel E, Rohrmoser M, et al. Partial purification and characterization of a toxic component of Amanita smithiana. Mycologia 1994; 86:555. file://www.cybertruffle.org.uk/cyberliber/index.htm (Accessed on October 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/12\">",
"      Chilton WS, Tsou G, De Cato L Jr, Malone MH. The unsaturated norleucines of Amanita solitaria. Chemical and pharmacological studies. Lloydia 1973; 36:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36759/abstract/13\">",
"      Beuhler MC, Sasser HC, Watson WA. The Outcome of North American Pediatric Unintentional Mushroom Ingestions with Various Decontamination Treatments: An Analysis of 14 Years of TESS Data. Toxicon 2009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13895 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36759=[""].join("\n");
var outline_f35_57_36759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24102788\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24102654\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24102661\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5480951\">",
"      MUSHROOM APPEARANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24102682\">",
"      PHARMACOTOXICOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5481816\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24102689\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24102696\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5483596\">",
"      Mushroom identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24102718\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24102710\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5483156\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24102726\">",
"      GI decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5483807\">",
"      Elimination enhancement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5483826\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5483840\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24102788\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13895|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/12/42178\" title=\"algorithm 1\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13895|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/37/10840\" title=\"picture 1\">",
"      Amanita smithiana and Tricholoma magnivelare mushroom",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13895|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/28/11727\" title=\"table 1\">",
"      Mushroom poisoning syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10698?source=related_link\">",
"      Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1786?source=related_link\">",
"      Clinical manifestations and evaluation of mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42615?source=related_link\">",
"      Management of mushroom poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_57_36760="The use of inhaler devices in children";
var content_f35_57_36760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The use of inhaler devices in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36760/contributors\">",
"     Robert H Moore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36760/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36760/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36760/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36760/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/57/36760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pressurized metered dose inhaler (pMDI) has been a mainstay in the treatment of respiratory diseases, especially asthma, since its introduction in 1956. It is the most commonly prescribed delivery system for administering inhaled bronchodilators and antiinflammatory agents worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Spacer devices, when used properly, substantially improve the delivery of pMDI-generated aerosols to the distal airways. The pMDI, used alone or in combination with a spacer or valved-holding chamber, is the most convenient and cost-effective way to administer aerosolized medications for most patients.",
"   </p>",
"   <p>",
"    Dry powder inhalers (DPI) are a separate group of medication aerosolizing devices widely used in the management of adult and pediatric pulmonary disease. These devices eliminate the need for propellants, and are less dependent upon coordination of inhalation and device actuation. Short- and long-acting beta agonists and inhaled glucocorticoids are available for administration via DPIs.",
"   </p>",
"   <p>",
"    The effectiveness of both delivery systems is dependent upon several factors, including the properties of the agent administered, design, temperature, humidity, and patient technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Device technique should be assessed during every encounter to ensure optimal use and drug delivery to the lungs. The use of pMDIs and DPIs in children is discussed here. Other aspects of aerosol therapy, including the use of nebulizers, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=see_link\">",
"     \"Delivery of inhaled medication in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRESSURIZED METERED DOSE INHALERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pMDI contains drug, which usually is either crystallized or in solution, along with the propellant and a surfactant (",
"    <a class=\"graphic graphic_picture graphicRef62613 \" href=\"mobipreview.htm?37/43/38591\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Propellants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 80 percent of the aerosol generated by a pMDI is propellant, historically a chlorofluorocarbon (CFC) such as freon. The cold blast resulting from the impact of particles in the pharynx (the cold-freon effect) when pMDIs containing CFC were actuated directly into the mouth caused some patients to abort the inhalation of drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, inhalation of CFC with pMDI was reported to promote paradoxical bronchoconstriction in some patients with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The international ban on CFCs (the Montreal Protocol) and the disadvantages described above prompted the development of other propellants, such as hydrofluoroalkanes (HFA), for use with pMDIs. In some cases (such as with HFA",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/40/35456?source=see_link\">",
"     beclomethasone",
"    </a>",
"    ), the use of HFA improves the delivery of drug to the lower airways and decreases deposition in the oropharynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/6\">",
"     6",
"    </a>",
"    ]. Similarly, the output of respirable particles from an HFA-",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    pMDI is superior to that from a pMDI containing CFC-albuterol when both are administered using a spacer device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Improved delivery to peripheral airways may necessitate the reduction of drug dose, particularly when using an inhaled glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Spacer devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     pMDI technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of aerosol delivery using a pMDI include convenient multidosing, portability, low cost, and a low risk of bacterial contamination. However, correct coordination of actuation and inspiration is crucial, and may be difficult for young children, patients with severe muscle weakness, or patients with hand deformities. Improper technique can increase oropharyngeal drug deposition and side effects.",
"   </p>",
"   <p>",
"    The effective delivery of drugs by pMDIs is technique-dependent. Unfortunately, up to two-thirds of patients and healthcare professionals who administer pMDI treatment do not use proper technique (",
"    <a class=\"graphic graphic_table graphicRef72362 \" href=\"mobipreview.htm?1/28/1484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2,10-14\">",
"     2,10-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"     \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10985460\">",
"    <span class=\"h2\">",
"     Priming the pMDI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Priming of all pMDIs is recommended before their initial use to ensure accurate mixing of propellant and medication in the metering chamber (",
"    <a class=\"graphic graphic_table graphicRef66821 \" href=\"mobipreview.htm?21/26/21933\">",
"     table 2",
"    </a>",
"    ). Priming involves the discharging of one or more doses of medication prior to use. pMDIs have extra doses to account for the initial priming [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/15\">",
"     15",
"    </a>",
"    ]. Additional priming may be recommended by the manufacturer if a period of time has elapsed between uses or if the pMDI is dropped.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Determining when an MDI is empty",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for the patient to have a means to determine when the canister is empty. It is not possible to determine when an MDI canister is empty by shaking it, because some propellant remains in the canister after all of the medication has been used. A few MDIs are now manufactured with integrated dose counters (",
"    <a class=\"graphic graphic_picture graphicRef51750 \" href=\"mobipreview.htm?5/38/5743\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/16\">",
"     16",
"    </a>",
"    ]. Another method of determining when the canister is empty is to have the patient maintain a log of the number of actuations, and to dispose of the device when the designated number of actuations has been reached or upon expiration, whichever is sooner. The technique of dropping the canister into a pan of water and observing how it floats is unreliable and is no longer recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Spacers and holding chambers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most problems associated with pMDI use, such as the need for coordination of actuation and inhalation, are related to the high velocity of discharge of particles from the nozzle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/4,19,20\">",
"     4,19,20",
"    </a>",
"    ]. The attachment of a spacer to the pMDI decreases the velocity of particles, and largely eliminates the need for coordination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ]. A spacer is usually an open-ended tube or bag that is of sufficient volume to allow the aerosol plume from the pMDI to expand, the propellant to evaporate, and large particles to settle (",
"    <a class=\"graphic graphic_picture graphicRef58957 \" href=\"mobipreview.htm?22/4/22607\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that adding a spacer improves drug delivery or efficacy as compared with a correctly used pMDI alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], but the addition of a spacer does correct for poor pMDI technique in most patients and allows faster resolution of symptoms in children with acute asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2,20,23-26\">",
"     2,20,23-26",
"    </a>",
"    ]. In addition, using a spacer markedly decreases oropharyngeal drug deposition and may reduce both oral and systemic side effects, especially when used with inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/20,27,28\">",
"     20,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of a spacer or valved holding chamber is recommended for all children in whom proper breath and actuation coordination is difficult (particularly those who are younger than five to six years), and whenever an inhaled glucocorticoid is being administered via a pMDI. A valved holding chamber with a mask is recommended for younger children, especially those under three years of age. Most children can be successfully changed to a chamber with mouthpiece as they get older. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Spacer devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spacer should be at least 100 to 700 mL in volume, and should provide a distance of 10 to 13 cm between the pMDI nozzle and the mouth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2\">",
"     2",
"    </a>",
"    ]. In a randomized crossover study of spacers with facemasks in children aged 10 to 25 months, a smaller volume 140 mL Aerochamber was less effective than the larger volume 260 mL Babyspacer and 750 mL Nebuhaler (filter dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    39.4, 53.5, and 55.5 mcg, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/29\">",
"     29",
"    </a>",
"    ]. However, using a large-volume spacer device may require longer administration times (up to 30 seconds) to empty the spacer. In another study of spacers without facemasks, children two to seven years of age had inhalation volumes nearly double the expected tidal volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/30\">",
"     30",
"    </a>",
"    ]. Two tidal breaths were sufficient for the smaller volume spacers (149 mL Aerochamber Plus and 225 mL Funhaler) and a 500 mL modified plastic soft drink bottle, but three tidal breaths were required for the larger volume spacer (750 mL Volumatic). Additional tidal breaths did not significantly increase drug delivery. Drug delivery was otherwise equivalent between the four devices. The modified 500 to 1000 mL plastic bottle is an approach that may be particularly useful in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/31-34\">",
"     31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of spacer devices are commercially available. Examples of these include Inspirease&reg;, Aerochamber&reg;, Nebuhaler&reg;, ACE&reg;, VORTEX&reg;, and Optihaler&reg;, among others (",
"    <a class=\"graphic graphic_picture graphicRef58957 \" href=\"mobipreview.htm?22/4/22607\">",
"     picture 3",
"    </a>",
"    ). The various spacers differ mainly with regard to size, shape, presence of a valve, and use of an inspiratory flow alarm (signaling too rapid inspiration).",
"   </p>",
"   <p>",
"    Plastic spacers have electrostatic charges within the chamber that attract particles and significantly reduce drug delivery to the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/7,35-38\">",
"     7,35-38",
"    </a>",
"    ]. This effect may be particularly important when starting bronchodilator therapy in acute asthma. One option is to use a nonelectrostatic metal spacer, where available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Alternatively, the electrostatic charge within the plastic spacer can be reduced by washing the spacer in a dilute solution (1:5000 or three to four drops in a gallon of water) of dishwashing detergent, without subsequent rinsing, prior to its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/37,41-43\">",
"     37,41-43",
"    </a>",
"    ]. The spacer also can be primed with several doses (10 to 20) of drug with the initial use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/7,37,44\">",
"     7,37,44",
"    </a>",
"    ], but this method generally is impractical given drug costs and limitations on refills, particularly with controller medications. These treatments improve drug delivery by as much as fourfold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/41,44\">",
"     41,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Valved-holding chambers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The valved-holding chamber is a specialized spacer that incorporates a one-way valve that permits aerosol removal from the chamber during inhalation and holds particles in the chamber during exhalation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/45\">",
"     45",
"    </a>",
"    ]. These devices can be fitted with a mouthpiece or a size-appropriate facemask, making them suitable for use in infants and young children. When using a facemask, it is important that it is well sealed and that dead space volume is minimized to assure optimal drug delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. Flexible masks appear to provide better seals and are associated with smaller dead space volume than rigid masks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. There is some evidence that a valved spacer may",
"    <strong>",
"     not",
"    </strong>",
"    be appropriate when using a pMDI in newborns and very small infants, due to their inability to reliably generate the inspiratory flow necessary to open the valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=see_link\">",
"     \"Delivery of inhaled medication in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Spacer technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other aerosol delivery devices, proper instruction in administering drugs via pMDIs with spacers is critical to achieve optimal effect. In one study, almost half of parents received inadequate instruction in spacer use for infants and young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/52\">",
"     52",
"    </a>",
"    ]. Although most of the parents thought the procedure was easy to understand, errors that affected the efficiency of medication administration were common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/52\">",
"     52",
"    </a>",
"    ]. The optimal technique for using a pMDI with spacer or valved-holding chamber is reviewed in the table (",
"    <a class=\"graphic graphic_table graphicRef72362 \" href=\"mobipreview.htm?1/28/1484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2,38,53\">",
"     2,38,53",
"    </a>",
"    ]. Factors that affect drug deposition of inhaled medications in infants and children are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=see_link\">",
"     \"Delivery of inhaled medication in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cleaning the spacer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic cleaning of the spacer is recommended, even though the powder residue that is deposited in the chamber is not harmful. When a plastic spacer is cleaned with water, an electrostatic charge that attracts aerosol particles is present during the first 10 to 20 actuations, reducing drug deposition in the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2\">",
"     2",
"    </a>",
"    ]. Washing the spacer in a dilute solution of dishwashing detergent, without subsequent rinsing, decreases static charge and improves drug delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/7,37,41,42\">",
"     7,37,41,42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Spacer devices'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Flow-triggered pMDIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Maxair Autohaler (3M) pMDI with the short-acting beta agonist",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/1/26?source=see_link\">",
"     pirbuterol",
"    </a>",
"    is the only flow-triggered pMDI available. Following the cocking of a lever, a dose is released when the patient's inspiratory flow rate exceeds 30",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    eliminating the need for coordination between actuation and breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/54\">",
"     54",
"    </a>",
"    ]. The disadvantage of this device is that the flow rate needed to trigger the release of drug may be too great for some children, especially those with acute bronchospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pressurized MDI or nebulizer?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinical trials and meta-analyses indicate that the administration of beta agonists via pMDI with spacer is at least as effective as, and possibly superior to, delivery of medication by jet nebulizer in reversing acute bronchospasm in infants and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/55-62\">",
"     55-62",
"    </a>",
"    ]. In addition, patients using a pMDI with spacer may experience fewer side effects (vomiting, tremors, hypoxemia, tachycardia) as compared with those using a jet nebulizer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/55,60,63,64\">",
"     55,60,63,64",
"    </a>",
"    ]. The advantages and disadvantages of pMDI and valved-holding chamber over nebulization are reviewed in the table [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/65,66\">",
"     65,66",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef52016 \" href=\"mobipreview.htm?37/51/38716\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pressurized MDIs were equal or superior to nebulizers in studies of small infants with bronchopulmonary dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/67\">",
"     67",
"    </a>",
"    ], wheezy infants between 4 and 12 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/58\">",
"     58",
"    </a>",
"    ], and young children with moderate to severe asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/68\">",
"     68",
"    </a>",
"    ], indicating the appropriateness of bronchodilator therapy via a pMDI and valved-holding chamber in all age groups. In young children with moderate to severe acute asthma, the pMDI with valved holding chamber produced a greater reduction in wheezing and significantly decreased the need for admission (33 percent versus 60 percent) as compared with the jet nebulizer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data suggest that four to six puffs of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    by pMDI and valved-holding chamber are therapeutically equivalent to 2.5 mg by jet nebulizer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In addition, the dose of drug delivered via pMDI with valved-holding chamber can be readily titrated to clinical effect, which may decrease side effects and reduce cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]. These data have led some authors to suggest that the pMDI with valved-holding chamber should be the preferred method for administering bronchodilators to infants and children with acute asthma at home, as well as in the emergency department and hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DRY POWDER INHALERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dry powder inhaler (DPI) is a breath-actuated device containing micronized drug particles with a mass median aerodynamic diameter (MMAD) of less than 5 &micro;m that are usually aggregated with carrier particles (such as lactose or glucose) of greater diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2,72\">",
"     2,72",
"    </a>",
"    ]. Drug is delivered to the airways by the inhalation of air over a punctured drug-containing capsule or blister.",
"   </p>",
"   <p>",
"    DPIs have several advantages compared with pMDI that are reviewed in the table (",
"    <a class=\"graphic graphic_table graphicRef52016 \" href=\"mobipreview.htm?37/51/38716\">",
"     table 3",
"    </a>",
"    ). DPI devices eliminate the requirement for propellants as well as for coordination between inhalation and device actuation. The clinical effects of drugs administered by DPI are similar to those administered by pMDI. This is true even when beta agonists are administered in the treatment of acute asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. There is evidence that at least some of these breath-actuated, dry-powder devices (eg, Turbuhaler) actually enhance pulmonary deposition of inhaled glucocorticoids and provide equal improvement in lung function at a lower dose compared with meter-dose inhalers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/75\">",
"     75",
"    </a>",
"    ]. In addition, oropharyngeal side effects appear to be less common when glucocorticoids are delivered by DPI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages of DPIs are reviewed in the table (",
"    <a class=\"graphic graphic_table graphicRef52016 \" href=\"mobipreview.htm?37/51/38716\">",
"     table 3",
"    </a>",
"    ). Relatively high inspiratory flow rates (30 to 120",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    are required to deaggregate and aerosolize the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2,72,77\">",
"     2,72,77",
"    </a>",
"    ]. In one study, the age at which most children who were inexperienced in the use of a DPI could generate a peak inspiratory flow rate of &ge;30",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    was four years and the age at which most children could generate a peak inspiratory flow rate of &ge;60",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    was nine years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/77\">",
"     77",
"    </a>",
"    ]. The requirement for an inspiratory flow rate of at least 28",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    makes these devices less useful in young children. In addition, the rapid inhalation that is required to insure optimal lung deposition, a technique different from that required for pMDIs, may be confusing for children who use both types of devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Device selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short- and long-acting beta agonists and inhaled glucocorticoids are available for administration via DPIs. A number of different types of DPIs are commercially available (",
"    <a class=\"graphic graphic_table graphicRef58951 \" href=\"mobipreview.htm?11/51/12093\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57922 \" href=\"mobipreview.htm?41/43/42675\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is a simple way to assess the ability of a child to use a DPI using a paper tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/78\">",
"     78",
"    </a>",
"    ]. A tissue is held in both hands and placed over the open mouth. The patient then inhales forcefully, creating a vacuum that keeps the tissue in place after letting go of the tissue. The goal is to keep the tissue in place on the mouth for five seconds while breathing in without holding the tissue.",
"   </p>",
"   <p>",
"    Several factors may influence the efficiency of drug delivery by DPIs. The age of the child and presence of asthma symptoms affect peak inspiratory flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/77,79\">",
"     77,79",
"    </a>",
"    ]. In addition, the design of the device affects the resistance to inspiration and the inspiratory flow required to aerosolize the medication. For instance, the Diskus is reliable at both low and high flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/77,80\">",
"     77,80",
"    </a>",
"    ], and may be suitable for use in children as young as four years of age and patients with severely impaired lung function (FEV1 less than 30 percent predicted) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/81\">",
"     81",
"    </a>",
"    ]. In contrast, high-resistance devices, such as the Turbuhaler, require greater inspiratory flow to efficiently aerosolize a high percentage of the nominal dose, and are not as reliable at lower inspiratory flow rates or in patients with severe airway obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/81\">",
"     81",
"    </a>",
"    ]. However, the Turbuhaler may provide better drug deposition to the lower airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36760/abstract/3,82\">",
"     3,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/52/13122?source=see_link\">",
"       \"Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/4/33858?source=see_link\">",
"       \"Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"       \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6864166\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two main types of inhaler devices used to administer aerosolized medications are the pressurized metered dose inhaler (pMDI) and the dry powder inhaler (DPI). The effectiveness of both delivery systems is dependent upon several factors, including the properties of the agent administered, design, temperature, humidity, and patient technique. Device technique should be assessed during every encounter to ensure optimal use and drug delivery to the lungs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=see_link\">",
"       \"Delivery of inhaled medication in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A pressurized metered dose inhaler (pMDI) contains drug, which is usually either crystallized or in solution, along with the propellant and a surfactant (",
"      <a class=\"graphic graphic_picture graphicRef62613 \" href=\"mobipreview.htm?37/43/38591\">",
"       picture 1",
"      </a>",
"      ). Advantages of aerosol delivery using a pMDI include convenient multidosing, portability, and a low risk of bacterial contamination (",
"      <a class=\"graphic graphic_table graphicRef52016 \" href=\"mobipreview.htm?37/51/38716\">",
"       table 3",
"      </a>",
"      ). However, correct coordination of actuation and inspiration is crucial (",
"      <a class=\"graphic graphic_table graphicRef72362 \" href=\"mobipreview.htm?1/28/1484\">",
"       table 1",
"      </a>",
"      ), and may be difficult for young children, patients with severe muscle weakness, or patients with hand deformities. Improper technique can increase oropharyngeal drug deposition and side effects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pressurized metered dose inhalers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most problems associated with pMDI use, such as the need for coordination of actuation and inhalation, are related to the high velocity of discharge of particles from the nozzle. The attachment of a spacer or valved holding chamber to the pMDI decreases the velocity of particles, and largely eliminates the need for coordination (",
"      <a class=\"graphic graphic_table graphicRef72362 \" href=\"mobipreview.htm?1/28/1484\">",
"       table 1",
"      </a>",
"      ). A spacer is usually an open-ended tube or bag that is of sufficient volume to allow the aerosol plume from the pMDI to expand, the propellant to evaporate, and large particles to settle (",
"      <a class=\"graphic graphic_picture graphicRef58957 \" href=\"mobipreview.htm?22/4/22607\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Spacers and holding chambers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many clinical trials and meta-analyses indicate that the administration of beta agonists via pMDI with spacer is at least as effective as, and possibly superior to, delivery of medication by jet nebulizer in reversing acute bronchospasm in infants and children. In addition, patients using a pMDI with spacer may experience fewer side effects compared with those using a jet nebulizer. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pressurized MDI or nebulizer?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A dry powder inhaler (DPI) is a breath-actuated device containing micronized drug (",
"      <a class=\"graphic graphic_table graphicRef58951 \" href=\"mobipreview.htm?11/51/12093\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57922 \" href=\"mobipreview.htm?41/43/42675\">",
"       picture 4",
"      </a>",
"      ). These devices eliminate the need for propellants, and are less dependent on coordination of inhalation and device actuation (",
"      <a class=\"graphic graphic_table graphicRef52016 \" href=\"mobipreview.htm?37/51/38716\">",
"       table 3",
"      </a>",
"      ). However, relatively high inspiratory flow rates are required to deaggregate and aerosolize the drug. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dry powder inhalers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/1\">",
"      Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001; 323:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/2\">",
"      Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000; 45:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/3\">",
"      Newman SP. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995; 8 Suppl 3:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/4\">",
"      Newman SP. Aerosol generators and delivery systems. Respir Care 1991; 36:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/5\">",
"      Yarbrough J, Mansfield LE, Ting S. Metered dose inhaler induced bronchospasm in asthmatic patients. Ann Allergy 1985; 55:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/6\">",
"      Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/7\">",
"      Chuffart AA, Sennhauser FH, Wildhaber JH, Swiss Paediatric Respiratory Physiology Research Group. Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers. Swiss Med Wkly 2001; 131:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/8\">",
"      Barry PW, O'Callaghan C. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. Eur Respir J 1997; 10:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/9\">",
"      Matthys H, Nowak D, Hader S, Kunkel G. Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 micrograms day-1 delivered as an extrafine aerosol in adults with moderate asthma. Respir Med 1998; 92 Suppl A:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/10\">",
"      Guidry GG, Brown WD, Stogner SW, George RB. Incorrect use of metered dose inhalers by medical personnel. Chest 1992; 101:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/11\">",
"      Larsen JS, Hahn M, Kochevar JW, et al. Administration errors with a conventional metered dose inhaler versus a novel breath actuated device. Ann Allergy 1993; 71:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/12\">",
"      Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 1994; 105:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/13\">",
"      Shrestha M, Parupia H, Andrews B, et al. Metered-dose inhaler technique of patients in an urban ED: prevalence of incorrect technique and attempt at education. Am J Emerg Med 1996; 14:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/14\">",
"      Jones JS, Holstege CP, Riekse R, et al. Metered-dose inhalers: do emergency health care providers know what to teach? Ann Emerg Med 1995; 26:308.",
"     </a>",
"    </li>",
"    <li>",
"     Ari A, Hess D, Myers TR, Rau JL. A guide to aerosol delivery devices for respiratory therapists, 2nd ed, American Assocation for Respiratory Care, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/16\">",
"      Rickard KA. Not running on empty. Ann Allergy Asthma Immunol 2006; 97:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/17\">",
"      Cain WT, Oppenheimer JJ. The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann Allergy Asthma Immunol 2001; 87:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/18\">",
"      Ogren RA, Baldwin JL, Simon RA. How patients determine when to replace their metered-dose inhalers. Ann Allergy Asthma Immunol 1995; 75:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/19\">",
"      Pedersen S, Mortensen S. Use of different inhalation devices in children. Lung 1990; 168 Suppl:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/20\">",
"      Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/21\">",
"      Levison H. Spacers in childhood asthma--is there one for all occasions? Ann Allergy 1990; 64:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/22\">",
"      Bowton DL. Metered-dose inhalers versus hand-held nebulizers. Some answers and new questions. Chest 1992; 101:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/23\">",
"      K&ouml;nig P. Spacer devices used with metered-dose inhalers. Breakthrough or gimmick? Chest 1985; 88:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/24\">",
"      Pedersen S. Aerosol treatment of bronchoconstriction in children, with or without a tube spacer. N Engl J Med 1983; 308:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/25\">",
"      Cunningham SJ, Crain EF. Reduction of morbidity in asthmatic children given a spacer device. Chest 1994; 106:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/26\">",
"      Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl 1982; 119:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/27\">",
"      Toogood JH, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984; 129:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/28\">",
"      Kim CS, Eldridge MA, Sackner MA. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. Am Rev Respir Dis 1987; 135:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/29\">",
"      Agertoft L, Pedersen S. Influence of spacer device on drug delivery to young children with asthma. Arch Dis Child 1994; 71:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/30\">",
"      Schultz A, Le Sou&euml;f TJ, Venter A, et al. Aerosol inhalation from spacers and valved holding chambers requires few tidal breaths for children. Pediatrics 2010; 126:e1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/31\">",
"      Zar HJ, Brown G, Donson H, et al. Home-made spacers for bronchodilator therapy in children with acute asthma: a randomised trial. Lancet 1999; 354:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/32\">",
"      Zar HJ, Weinberg EG, Binns HJ, et al. Lung deposition of aerosol--a comparison of different spacers. Arch Dis Child 2000; 82:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/33\">",
"      Zar HJ, Liebenberg M, Weinberg EG, et al. The efficacy of alternative spacer devices for delivery of aerosol therapy to children with asthma. Ann Trop Paediatr 1998; 18:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/34\">",
"      Teo J, Kwang LW, Yip WC. An inexpensive spacer for use with metered-dose bronchodilators in young asthmatic children. Pediatr Pulmonol 1988; 5:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/35\">",
"      Wildhaber JH, Devadason SG, Eber E, et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996; 51:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/36\">",
"      Anh&oslash;j J, Bisgaard H, Lipworth BJ. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br J Clin Pharmacol 1999; 47:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/37\">",
"      Wildhaber JH, Devadason SG, Hayden MJ, et al. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur Respir J 1996; 9:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/38\">",
"      Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995; 40:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/39\">",
"      Bisgaard H. A metal aerosol holding chamber devised for young children with asthma. Eur Respir J 1995; 8:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/40\">",
"      Bisgaard H, Anh&oslash;j J, Klug B, Berg E. A non-electrostatic spacer for aerosol delivery. Arch Dis Child 1995; 73:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/41\">",
"      Pi&eacute;rart F, Wildhaber JH, Vrancken I, et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999; 13:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/42\">",
"      Wildhaber JH, Janssens HM, Pi&eacute;rart F, et al. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000; 29:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/43\">",
"      Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respir Care 2007; 52:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/44\">",
"      Kenyon CJ, Thorsson L, Borgstr&ouml;m L, Newman SP. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J 1998; 11:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/45\">",
"      Rubin BK, Fink JB. Aerosol therapy for children. Respir Care Clin N Am 2001; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/46\">",
"      Amirav I, Newhouse MT. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 2001; 108:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/47\">",
"      Hayden JT, Smith N, Woolf DA, et al. A randomised crossover trial of facemask efficacy. Arch Dis Child 2004; 89:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/48\">",
"      Shah SA, Berlinski AB, Rubin BK. Force-dependent static dead space of face masks used with holding chambers. Respir Care 2006; 51:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/49\">",
"      Amirav I, Newhouse MT. Review of optimal characteristics of face-masks for valved-holding chambers (VHCs). Pediatr Pulmonol 2008; 43:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/50\">",
"      Chavez A, McCracken A, Berlinski A. Effect of face mask dead volume, respiratory rate, and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol 2010; 45:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/51\">",
"      Fok TF, Lam K, Chan CK, et al. Aerosol delivery to non-ventilated infants by metered dose inhaler: should a valved spacer be used? Pediatr Pulmonol 1997; 24:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/52\">",
"      Marguet C, Couderc L, Le Roux P, et al. Inhalation treatment: errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children. Pediatr Allergy Immunol 2001; 12:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/53\">",
"      Barry PW, Robertson CF, O'Callaghan C. Optimum use of a spacer device. Arch Dis Child 1993; 69:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/54\">",
"      Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/55\">",
"      Lin YZ, Hsieh KH. Metered dose inhaler and nebuliser in acute asthma. Arch Dis Child 1995; 72:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/56\">",
"      Rubilar L, Castro-Rodriguez JA, Girardi G. Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age. Pediatr Pulmonol 2000; 29:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/57\">",
"      Schuh S, Johnson DW, Stephens D, et al. Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr 1999; 135:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/58\">",
"      Wildhaber JH, Devadason SG, Hayden MJ, et al. Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol 1997; 23:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/59\">",
"      Closa RM, Ceballos JM, G&oacute;mez-Pap&iacute; A, et al. Efficacy of bronchodilators administered by nebulizers versus spacer devices in infants with acute wheezing. Pediatr Pulmonol 1998; 26:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/60\">",
"      Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med 1995; 149:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/61\">",
"      Castro-Rodriguez JA, Rodrigo GJ. beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr 2004; 145:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/62\">",
"      Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006; :CD000052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/63\">",
"      Deerojanawong J, Manuyakorn W, Prapphal N, et al. Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer in young children with wheezing. Pediatr Pulmonol 2005; 39:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/64\">",
"      Rodrigo C, Rodrigo G. Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer. Am J Emerg Med 1998; 16:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/65\">",
"      Benton G, Thomas RC, Nickerson BG, et al. Experience with a metered-dose inhaler with a spacer in the pediatric emergency department. Am J Dis Child 1989; 143:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/66\">",
"      Hickey RW, Gochman RF, Chande V, Davis HW. Albuterol delivered via metered-dose inhaler with spacer for outpatient treatment of young children with wheezing. Arch Pediatr Adolesc Med 1994; 148:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/67\">",
"      Fok TF, Monkman S, Dolovich M, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1996; 21:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/68\">",
"      Leversha AM, Campanella SG, Aickin RP, Asher MI. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatr 2000; 136:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/69\">",
"      Mandelberg A, Tsehori S, Houri S, et al. Is nebulized aerosol treatment necessary in the pediatric emergency department? Chest 2000; 117:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/70\">",
"      Newhouse MT. Asthma therapy with aerosols: are nebulizers obsolete? A continuing controversy. J Pediatr 1999; 135:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/71\">",
"      Kercsmar CM. Aerosol treatment of acute asthma: and the winner is... J Pediatr 2000; 136:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/72\">",
"      Dhand R. Aerosol therapy for asthma. Curr Opin Pulm Med 2000; 6:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/73\">",
"      Nana A, Youngchaiyud P, Maranetra N, et al. Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998; 92:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/74\">",
"      Drblik S, Lapierre G, Thivierge R, et al. Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode. Arch Dis Child 2003; 88:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/75\">",
"      Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/76\">",
"      Selroos O, Backman R, Fors&eacute;n KO, et al. Local side-effects during 4-year treatment with inhaled corticosteroids--a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy 1994; 49:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/77\">",
"      Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 2005; 39:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/78\">",
"      Amirav I, Newhouse MT. To inhale or not to inhale: is that the question? A simple method of DPI instruction. J Pediatr 2010; 156:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/79\">",
"      Kamps AW, Brand PL, Roorda RJ. Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol 2004; 37:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/80\">",
"      Nielsen KG, Auk IL, Bojsen K, et al. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J 1998; 11:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/81\">",
"      Burnell PK, Small T, Doig S, et al. Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med 2001; 95:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36760/abstract/82\">",
"      Svartengren K, Lindestad P, Svartengren M, et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 1995; 152:32.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5738 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36760=[""].join("\n");
var outline_f35_57_36760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6864166\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRESSURIZED METERED DOSE INHALERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Propellants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      pMDI technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10985460\">",
"      Priming the pMDI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Determining when an MDI is empty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Spacers and holding chambers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Spacer devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Valved-holding chambers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Spacer technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cleaning the spacer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Flow-triggered pMDIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pressurized MDI or nebulizer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DRY POWDER INHALERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Device selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6864166\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5738|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/43/38591\" title=\"picture 1\">",
"      Metered dose inhaler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/38/5743\" title=\"picture 2\">",
"      MDI with counter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/4/22607\" title=\"picture 3\">",
"      MDI spacers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/43/42675\" title=\"picture 4\">",
"      Dry powder inhalers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/28/1484\" title=\"table 1\">",
"      Metered dose inhaler technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/26/21933\" title=\"table 2\">",
"      pMDI priming requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/51/38716\" title=\"table 3\">",
"      Comparison of aerosol devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/51/12093\" title=\"table 4\">",
"      Dry powder inhaler technique in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=related_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/52/13122?source=related_link\">",
"      Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/4/33858?source=related_link\">",
"      Patient information: How to use your child&rsquo;s metered dose inhaler (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30376?source=related_link\">",
"      Use of medication nebulizers in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_57_36761="Methadone: Drug information";
var content_f35_57_36761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methadone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/13/4310?source=see_link\">",
"    see \"Methadone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/49/22296?source=see_link\">",
"    see \"Methadone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dolophine&reg;;",
"     </li>",
"     <li>",
"      Methadone Diskets&reg;;",
"     </li>",
"     <li>",
"      Methadone Intensol&trade;;",
"     </li>",
"     <li>",
"      Methadose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metadol-D&trade;;",
"     </li>",
"     <li>",
"      Metadol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Regulations regarding methadone use may vary by state and/or country. Obtain advice from appropriate regulatory agencies and/or consult with pain management/palliative care specialists.",
"     <b>",
"      Note:",
"     </b>",
"     These are guidelines and do not represent the maximum doses that may be required. Consider total daily dose, potency, prior opioid use, degree of opioid experience and tolerance, conversion from previous opioid, patient&rsquo;s general condition, concurrent medications, and type and severity of pain during prescribing process. Other factors to consider:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Interpatient variability in absorption, metabolism, and relative analgesic potency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Population-based equianalgesic conversion ratios between methadone and other opioids may not be completely accurate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Duration of analgesic action is much shorter than plasma elimination half-life.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Steady-state plasma concentrations and full analgesic effects are not attained until 3-5 days after initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull;	Methadone has a narrow therapeutic index.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When pain management is no longer required, do not abruptly discontinue. Reduce dose every 2-4 days to prevent signs or symptoms of withdrawal. With detoxification treatment, abrupt discontinuation may lead to relapse of illicit drug use in susceptible patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic pain (moderate-to-severe):",
"     </b>",
"     Opioid-naive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 2.5-10 mg every 8-12 hours; more frequent administration may be required during initiation to maintain adequate analgesia (manufacturer&rsquo;s labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 2.5 mg every 8-12 hours; titrate slowly to effect; may also be administered by SubQ or I.M. injection (manufacturer&rsquo;s labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic pain (CPSO, 2000; VA/DoD, 2003):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Opioid-naive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Gradual titration (for chronic noncancer pain and situations where frequent monitoring is unnecessary):",
"     </i>",
"     Initial: 2.5 mg every 8 hours; may increase dosing interval to every 12 hours (in about 4-5 days); may increase dose by 2.5 mg per dose every 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Faster titration (for cancer pain and situations where frequent monitoring is possible):",
"     </i>",
"     Initial: 2.5 mg every 6-8 hours; may increase dosing interval to every 8-12 hours (in about 4-5 days); may increase dose by 2.5 mg per dose as often as every day over about 4 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Opioid-tolerant:",
"     <b>",
"      <i>",
"       Conversion from oral morphine to oral methadone:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     1) There is not a linear relationship when converting to methadone from oral morphine. The higher the daily morphine equivalent dose the more potent methadone is, and 2) conversion to methadone is more of a process than a calculation. In general, the starting methadone dose should not exceed 30-40 mg/day, even in patients on high doses of other opioids. Patient response to methadone needs to be monitored closely throughout the process of the conversion. There are several proposed ratios for converting from oral morphine to oral methadone (Ayonrinde, 2000; Mercadente, 2001; Ripamonti, 1998). The manufacturer of Dolophine&reg; recommends the following conversion for chronic administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Daily oral morphine dose &lt;100 mg:",
"     </i>",
"     Estimated daily oral methadone dose: 20% to 30% of total daily morphine dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Daily oral morphine dose",
"     </i>",
"     100-300 mg: Estimated daily oral methadone dose: 10% to 20% of total daily morphine dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Daily oral morphine dose",
"     </i>",
"     300-600 mg: Estimated daily oral methadone dose: 8% to 12% of total daily morphine dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Daily oral morphine dose",
"     </i>",
"     600-1000 mg: Estimated daily oral methadone dose: 5% to 10% of total daily morphine dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Daily oral morphine dose",
"     </i>",
"     &gt;1000 mg: Estimated daily oral methadone dose: &lt;5% of total daily morphine dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The estimated total daily methadone dose should then be divided to reflect the intended dosing schedule (eg, divide by 3 and administer every 8 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Conversion from oral to parenteral dose:",
"      </i>",
"     </b>",
"     Initial dose: Parenteral:Oral ratio: 1:2 (eg, 5 mg parenteral methadone equals 10 mg oral methadone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Critically-ill patients (unlabeled use; Barr, 2013):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     May be used to slow development of tolerance when escalation with other opioids is required. Enteral methadone has also been used to wean prolonged continuous opioid infusions (Al Qadheeb, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral: 10-40 mg every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V.: 2.5-10 mg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Detoxification:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Initial: A single dose of 20-30 mg is usually sufficient to suppress symptoms. Should not exceed 30 mg; lower doses should be considered in patients with low tolerance at initiation (eg, absence of opioids &ge;5 days); an additional 5-10 mg of methadone may be provided if withdrawal symptoms have not been suppressed or if symptoms reappear after 2-4 hours; total daily dose on the first day should not exceed 40 mg. Do not increase dose without waiting for steady-state to be achieved. Levels will accumulate over the first few days. Reassure the patient that duration of effect will increase as methadone accumulates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Maintenance: Titrate to a dosage which prevents craving, attenuates euphoric effect of self-administered opiates, and tolerance to sedative effects of methadone. Usual range: 80-120 mg/day (titration should occur cautiously)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Withdrawal: Dose reductions should be &lt;10% of the maintenance dose, every 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Detoxification (short-term):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Initial: Titrate to ~40 mg/day in divided doses to achieve stabilization. May continue 40 mg dose for 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Maintenance: Titrate to a dosage which prevents/attenuates euphoric effects of self-administered opioids, reduces drug craving, and withdrawal symptoms are prevented for 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Withdrawal: Requires individualization. Decrease daily or every other day, keeping withdrawal symptoms tolerable; hospitalized patients may tolerate a 20% reduction/day; ambulatory patients may require a slower reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment during pregnancy:",
"     </b>",
"     Methadone dose may need to be increased, or the dosing interval decreased; see Pregnancy Considerations - use should be reserved for cases where the benefits clearly outweigh the risks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.M.: 2.5 mg every 8-12 hours; refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F194003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Unlabeled dosing (Aronoff, 2007): Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% to 75% of normal dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F194004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, undergoes hepatic metabolism and systemic exposure may be increased after repeated dosing. Avoid in severe liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6821704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Excessive opioid-related adverse events:",
"     </i>",
"     Reduce next dose. Assess and reduce both the maintenance dose and dosing interval if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      QT",
"      <sub>",
"       c",
"      </sub>",
"      prolongation (Krantz, 2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;450-499 msecs: Monitor QT",
"     <sub>",
"      c",
"     </sub>",
"     more frequently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &ge;500 msecs: Consider discontinuation or reducing methadone dose",
"     <b>",
"      or",
"     </b>",
"     eliminate factors promoting QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (eg, potassium-wasting drugs)",
"     <b>",
"      or",
"     </b>",
"     use alternative therapy (eg, buprenorphine)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride [concentrate]: 10 mg/mL (946 mL, 1000 mL, 1000s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadone Intensol&trade;: 10 mg/mL (30 mL) [dye free, sugar free; contains sodium benzoate; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadose&reg;: 10 mg/mL (1000 mL) [contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadose&reg;: 10 mg/mL (1000 mL) [dye free, sugar free; contains sodium benzoate; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dolophine&reg;: 5 mg, 10 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, dispersible, oral, as hydrochloride: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadone Diskets&reg;: 40 mg [scored; orange-pineapple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadose&reg;: 40 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F194038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     When used for treatment of opioid addiction: May only be dispensed in accordance to guidelines established by the Substance Abuse and Mental Health Services Administration&rsquo;s (SAMHSA) Center for Substance Abuse Treatment (CSAT). Regulations regarding methadone use may vary by state and/or country. Obtain advice from appropriate regulatory agencies and/or consult with pain management/palliative care specialists.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Regulatory Exceptions to the General Requirement to Provide Opioid Agonist Treatment (per manufacturer's labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1. During inpatient care, when the patient was admitted for any condition other than concurrent opioid addiction, to facilitate the treatment of the primary admitting diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2. During an emergency period of no longer than 3 days while definitive care for the addiction is being sought in an appropriately licensed facility.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14624980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dolophine&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311370.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311370.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F193975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral dose for detoxification and maintenance may be administered in fruit juice or water. Dispersible tablet should not be chewed or swallowed; add to liquid and allow to dissolve before administering. May rinse if residual remains. Injectable solution can be administered I.M., SubQ, or I.V.; rate of I.V. administration not defined.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F194044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Atropine, dexamethasone sodium phosphate, diazepam, diphenhydramine, haloperidol, hydroxyzine, ketorolac, lorazepam, methotrimeprazine, metoclopramide, midazolam, phenobarbital, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Phenytoin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time; detoxification and maintenance treatment of opioid addiction through a certified program",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methadone may be confused with dexmethylphenidate, Mephyton&reg;, methylphenidate, Metadate CD&reg;, Metadate&reg; ER, metolazone, morphine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. During prolonged administration, adverse effects may decrease over several weeks; however, constipation and sweating may persist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bigeminal rhythms, bradycardia, cardiac arrest, cardiomyopathy, ECG changes, edema, extrasystoles, faintness, flushing, heart failure, hypotension, palpitation,peripheral vasodilation, phlebitis, orthostatic hypotension, QT interval prolonged, shock, syncope, tachycardia, torsade de pointes, T-wave inversion, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, disorientation, dizziness, drowsiness, dysphoria, euphoria, hallucination, headache, insomnia,  lightheadedness, sedation, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hemorrhagic urticaria, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic effect, amenorrhea, hypokalemia, hypomagnesemia, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, biliary tract spasm, constipation, glossitis, nausea, stomach cramps, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary retention or hesitancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (reversible, reported in patients with chronic hepatitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: I.M./SubQ injection: Erythema, pain, swelling; I.V. injection: Hemorrhagic urticaria (rare),  pruritus, urticaria, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema, respiratory depression, respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Death, diaphoresis, physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methadone or any component of the formulation; significant respiratory depression (in the absence of resuscitative equipment or in an unmonitored setting); acute or severe bronchial asthma (in the absence of resuscitative equipment or in an unmonitored setting) or hypercarbia; known or suspected paralytic ileus; concurrent use of selegiline (Ensam&reg; product labeling)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Methadone is not to be used on an as-needed basis; it is not for pain that is mild or not expected to persist; it is not for acute pain or postoperative pain.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Avoid use in patients with underlying CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation:",
"     <b>",
"      [U.S. Boxed Warning]: QT",
"      <sub>",
"       c",
"      </sub>",
"      interval prolongation and serious arrhythmias (eg, torsade de pointes) have occurred during treatment. Most cases involve patients being treated for pain with large, multiple daily doses.",
"     </b>",
"     Patients should be informed of the potential arrhythmia risk, evaluated for any history of structural heart disease, arrhythmia, syncope, and for existence of potential drug interactions including drugs that possess QT",
"     <sub>",
"      c",
"     </sub>",
"     interval-prolonging properties, promote hypokalemia, hypomagnesemia, or hypocalcemia, or reduce elimination of methadone (eg, CYP3A4 inhibitors). Obtain baseline ECG for all patients and risk stratify according to QT",
"     <sub>",
"      c",
"     </sub>",
"     interval (see Monitoring Parameters). Use with caution in patients at risk for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, with medications known to prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, promote electrolyte depletion, or inhibit CYP3A4, or history of conduction abnormalities. QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prolongation and torsade de pointes may be associated with doses &gt;200 mg/day, but have also been observed with lower doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression:",
"     <b>",
"      [U.S. Boxed Warning]: Fatal respiratory depression has occurred with the highest risk at initiation and with dosage increases.",
"     </b>",
"     Populations of special concern are the elderly, cachectic, and debilitated. Use extreme caution during treatment initiation, dose titration, and conversion from other opioid agonists to methadone; monitor for respiratory depression especially during initiation and titration. Peak respiratory depressant effects occur later and persist longer than peak analgesic effects possibly contributing to cases of iatrogenic overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. Avoid use in patients with obstruction. Use is contraindicated with known or suspected paralytic ileus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anxiety disorders: Methadone is ineffective for the relief of anxiety.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction including acute pancreatitis; may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression or suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse:",
"     <b>",
"      [U.S. Boxed Warning]: Monitor for signs of misuse, abuse or addiction.",
"     </b>",
"     Assess patient&rsquo;s abuse potential based upon personal or family history of substance abuse or addiction (drug or ethanol) or mental illness (eg, major depressive disorder). Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury or increased intracranial pressure (ICP): Use with extreme caution in patients with head injury, brain tumor, or elevated ICP; reduced respiratory drive and resultant CO",
"     <sub>",
"      2",
"     </sub>",
"     retention can increase ICP.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; avoid with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioid addiction:",
"     <b>",
"      [U.S. Boxed Warning]: When used for treatment of opioid addiction (detoxification or maintenance), may only be dispensed by certified opioid treatment programs.",
"     </b>",
"     These programs must be certified by the designated state authority; exceptions include inpatient treatment of other conditions and emergency period (not &gt;3 days) while definitive substance abuse treatment is being sought.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urethral stricture: Use with caution in patients with prostatic hyperplasia and/or urethral stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Contraindicated in patients with respiratory depression and in those with conditions that increase the risk of life-threatening respiratory depression. Use with caution in patients with respiratory disease or pre-existing respiratory conditions (eg, severe obesity, asthma, COPD, sleep apnea, CNS depression), kyphoscoliosis, or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with seizure disorders; may induce or aggravate seizures. Monitor for seizure control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients receiving concurrent use of medications known to inhibit CYP3A4, prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, or promote hypokalemia, hypomagnesemia, or hypocalcemia; may require dosage adjustments or use of alternative therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol. Initiate methadone at a lower dose than usual; consider lowering dose of other CNS depressant. Monitor for signs of excessive sedation or respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects, particularly respiratory depression. Decrease initial dose and monitor closely when initiating and titrating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Fatal overdose can result from accidental ingestion, especially in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tablets:",
"     <b>",
"      [U.S. Boxed Warning]: For oral administration only;",
"     </b>",
"     excipients to deter use by injection are contained in tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should only be prescribed by healthcare professionals who are knowledgeable in the use of potent opioids for chronic pain management.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Incomplete cross-tolerance: Use caution in converting patients from other opioids to methadone. Follow appropriate conversion schedules. Patients tolerant to other mu opioid agonists may not be tolerant to methadone and at risk for severe respiratory depression when converted to methadone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms. Gradually taper dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Methadone. Boceprevir may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Methadone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Methadone may decrease the serum concentration of Didanosine.  Management: If use of methadone with didanosine is necessary, enteric coated didanosine is preferred.  Avoid using didanosine powder for solution with methadone.  Increased monitoring of clinical response to didanosine (including viral load) is necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Methadone. Management: Methadone dose reduction may be necessary when used with fluconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons (Alfa): May increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Methadone. Management: Methadone dose reduction may be necessary when used with ketoconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Methadone. Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the QTc-prolonging effect of Methadone. Posaconazole may increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Methadone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atazanavir; Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the metabolism of Methadone. Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Delavirdine; Etravirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Methadone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Methadone. Management: Methadone dose reduction may be necessary when used with voriconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Methadone may increase the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F193992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit/grapefruit juice may increase levels of methadone. Management: Avoid concurrent use of grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease methadone levels and increase CNS depression; valerian, kava kava, and gotu kola may increase CNS depression. Management: Avoid St John's wort, valerian, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some, but not all, animal studies. Data collected by the Teratogen Information System are complicated by maternal use of illicit drugs, nutrition, infection, and psychosocial circumstances. However, pregnant women in methadone treatment programs are reported to have improved fetal outcomes compared to pregnant women using illicit drugs. Methadone can be detected in the amniotic fluid, cord plasma, and newborn urine. Fetal growth, birth weight, length, and/or head circumference may be decreased in infants born to narcotic-addicted mothers treated with methadone during pregnancy. Growth deficits do not appear to persist; however, decreased performance on psychometric and behavioral tests has been found to continue into childhood. Abnormal fetal nonstress tests have also been reported. Withdrawal symptoms in the neonate may be observed up to 2-4 weeks after delivery. The manufacturer states that methadone should be used during pregnancy only if clearly needed. Because methadone clearance in pregnant women is increased and half-life is decreased during the 2nd and 3rd trimesters of pregnancy, withdrawal symptoms may be observed in the mother; dosage of methadone may need increased or dosing interval decreased during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F193981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peak methadone levels appear in breast milk 4-5 hours after an oral dose. Methadone has been detected in the plasma of some breast-fed infants whose mothers are taking methadone. Use during breast-feeding is not recommended, and the manufacturer recommends that women on high dose methadone maintenance who already are breast-feeding be instructed to wean breast-feeding gradually to avoid neonatal abstinence syndrome. Sedation and respiratory depression have been reported in nursing infants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Methadone HCl Intensol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (30 mL): $25.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Methadone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1000 mL): $104.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Methadose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1000 mL): $104.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Methadose Sugar-Free Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1000 mL): $104.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methadone HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (20 mL): $171.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methadone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (500 mL): $39.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (500 mL): $69.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet,Dispersible",
"     </b>",
"     (Methadone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $33.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet,Dispersible",
"     </b>",
"     (Methadose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $33.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dolophine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $12.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $21.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methadone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $8.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $19.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methadose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $14.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Assess efficacy of pain control; vital signs and mental status; signs of drug abuse, addiction, or diversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Obtain baseline ECG (evaluate QT",
"     <sub>",
"      c",
"     </sub>",
"     interval), within 30 days of initiation, and then annually for all patients receiving methadone. Increase ECG monitoring if patient receiving &gt;100 mg/day or if unexplained syncope or seizure occurs while on methadone (Krantz, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      If before or at anytime during therapy (Krantz, 2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;450-499 msecs: Discuss potential risks and benefits; monitor QT",
"     <sub>",
"      c",
"     </sub>",
"     more frequently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &ge;500 msecs: Consider discontinuation or reducing methadone dose",
"     <b>",
"      or",
"     </b>",
"     eliminate factors promoting QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (eg, potassium-wasting drugs)",
"     <b>",
"      or",
"     </b>",
"     use alternative therapy (eg, buprenorphine)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F193971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of opiate withdrawal: Therapeutic: 100-400 ng/mL (SI: 0.32-1.29 micromole/L); Toxic: &gt;2 mcg/mL (SI: &gt;6.46 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adolan (IL);",
"     </li>",
"     <li>",
"      Amidona (CN);",
"     </li>",
"     <li>",
"      Aseptone (MY);",
"     </li>",
"     <li>",
"      Bennaston (MY);",
"     </li>",
"     <li>",
"      Biodone (NZ);",
"     </li>",
"     <li>",
"      Biodone Extra Forte (NZ);",
"     </li>",
"     <li>",
"      Biodone Forte (AU, NZ);",
"     </li>",
"     <li>",
"      Depridol (HN, HU);",
"     </li>",
"     <li>",
"      Dolmed (FI);",
"     </li>",
"     <li>",
"      Eptadone (GB, IT);",
"     </li>",
"     <li>",
"      Gobbidona (AR);",
"     </li>",
"     <li>",
"      Heptadon (AT);",
"     </li>",
"     <li>",
"      Heptanon (HR);",
"     </li>",
"     <li>",
"      Ketalgin (CH);",
"     </li>",
"     <li>",
"      Mephenon (BE, LU);",
"     </li>",
"     <li>",
"      Metacalmans (AR);",
"     </li>",
"     <li>",
"      Metadol (PE);",
"     </li>",
"     <li>",
"      Metadon (DK, EE, NO, SE);",
"     </li>",
"     <li>",
"      Metasedin (ES);",
"     </li>",
"     <li>",
"      Methaddict (DE);",
"     </li>",
"     <li>",
"      Methadone chlorhydrate (FR);",
"     </li>",
"     <li>",
"      Methadone Hydrochloride (PL);",
"     </li>",
"     <li>",
"      Methadose (CO);",
"     </li>",
"     <li>",
"      Mytadon Cristalia (UY);",
"     </li>",
"     <li>",
"      Mytedom (BR);",
"     </li>",
"     <li>",
"      Pallidone (NZ);",
"     </li>",
"     <li>",
"      Phymet DTF (IE);",
"     </li>",
"     <li>",
"      Phymet DTF Syrup (AU);",
"     </li>",
"     <li>",
"      Physeptone (AU, GB);",
"     </li>",
"     <li>",
"      Rubidexol (MX);",
"     </li>",
"     <li>",
"      Symoron (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression. Methadone has also been shown to have weak N-methyl-D-aspartate (NMDA) receptor antagonism (Callahan, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Analgesic: 0.5-1 hour; Parenteral: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Parenteral: 1-2 hours; Oral: Continuous dosing: 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of analgesia: Oral: 4-8 hours (single-dose studies), increases to 22-48 hours with repeated doses; slow release from the liver and other tissues may prolong duration of action",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Lipophilic; V",
"     <sub>",
"      dss",
"     </sub>",
"     : 1-8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 90% primarily to alpha-1 acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; N-demethylation primarily via CYP3A4, CYP2B6, and CYP2C19 to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 36% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 8-59 hours; may be prolonged with alkaline pH, decreased during pregnancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1-7.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;10% as unchanged drug); increased with urine pH &lt;6",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Al-Qadheeb NS, Roberts RJ, Griffin R, et al, &ldquo;Impact of Enteral Methadone on the Ability to Wean Off Continuously Infused Opioids in Critically Ill, Mechanically Ventilated Adults: A Case-Control Study,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2012, 46(9):1160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/22872749/pubmed\" id=\"22872749\" target=\"_blank\">",
"        22872749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anand KJ and Arnold JH, &ldquo;Opioid Tolerance and Dependence in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1994, 22(2):334-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/8306694/pubmed\" id=\"8306694\" target=\"_blank\">",
"        8306694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, p 19.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ayonrinde OT and Bridge DT, \"The Rediscovery of Methadone for Cancer Pain Management,\" Med J Aust, 2000, 173(10):536-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/11194738/pubmed\" id=\"11194738\" target=\"_blank\">",
"        11194738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Callahan RJ, Au JD, Paul M, et al, &ldquo;Functional Inhibition by Methadone of N-Methyl-D-Aspartate Receptors Expressed in Xenopus Oocytes: Stereospecific and Subunit Effects,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2004, 98(3):653-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/14980914/pubmed\" id=\"14980914\" target=\"_blank\">",
"        14980914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chou R, Fanciullo GJ, Fine PG, et al, \"Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,\"",
"      <i>",
"       J Pain",
"      </i>",
"      , 2009, 10(2):113-30. Available at file://www.jpain.org/article/S1526-5900(08)00831-6/fulltext",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/19187889/pubmed\" id=\"19187889\" target=\"_blank\">",
"        19187889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      College of Physicians and Surgeons of Ontario (CPSO), \"Evidence-Based Recommendations for Medical Management of Chronic Non-Malignant Pain: Reference Guide for Physicians,\" 2000. Available at file://www.cpso.on.ca/uploadedFiles/policies/guidelines/methadone/MedicalManagementPain.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Health and Human Services: Substance Abuse and Mental Health Services Administration, &ldquo;Opioid Drugs in Maintenance and Detoxification of Opiate Addiction; Final Rule,&rdquo;",
"      <i>",
"       Fed Regist",
"      </i>",
"      , 2001, 66(11):4076-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/11503765/pubmed\" id=\"11503765\" target=\"_blank\">",
"        11503765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Veteran Affairs and Department of Defense, &ldquo;Clinical Practice Guideline, Management of Opioid Therapy for Chronic Pain,\" 2010. Available at",
"      <a href=\"file://www.healthquality.va.gov/Chronic_Opioid_Therapy_COT.asp\" target=\"_blank\">",
"       file://www.healthquality.va.gov/Chronic_Opioid_Therapy_COT.asp",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Veteran Affairs and Department of Defense, \"VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders (SUD),&rdquo;  2009. Available at",
"      <a href=\"file://www.healthquality.va.gov/Substance_Use_Disorder_SUD.asp\" target=\"_blank\">",
"       file://www.healthquality.va.gov/Substance_Use_Disorder_SUD.asp",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrell BA, &ldquo;Pain Management in Elderly People,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1991, 39(1):64-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/1670940/pubmed\" id=\"1670940\" target=\"_blank\">",
"        1670940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gayle MO, Ryan CA, and Nazarali S, &ldquo;Unusual Cause of Methadone Poisoning,&rdquo;",
"      <i>",
"       Acta Paediatr Scand",
"      </i>",
"      , 1991, 80(4):486-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/2058403/pubmed\" id=\"2058403\" target=\"_blank\">",
"        2058403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gazelle G and Fine PG, &ldquo;Methadone for the Treatment of Pain #75,&rdquo;",
"      <i>",
"       J Palliat Med",
"      </i>",
"      , 2003, 6(4):620-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/14516505/pubmed\" id=\"14516505\" target=\"_blank\">",
"        14516505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krantz MJ, Martin J, Stimmel B, et al, \"QTc Interval Screening in Methadone Treatment,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(6):387-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/19153406/pubmed\" id=\"19153406\" target=\"_blank\">",
"        19153406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauriault G, LeBelle MJ, Lodge BA, et al, &ldquo;Stability of Methadone in Four Vehicles for Oral Administration,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1991, 48(6):1252-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/1858805/pubmed\" id=\"1858805\" target=\"_blank\">",
"        1858805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Management of Opioid Therapy for Chronic Pain Working Group, \"VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain,\" 2010. Available at",
"      <a href=\"file://www.healthquality.va.gov/COT_312_Full-er.pdf\" target=\"_blank\">",
"       file://www.healthquality.va.gov/COT_312_Full-er.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mercadante S, Casuccio A, Fulfaro F, et al, &ldquo;Switching from Morphine to Methadone to Improve Analgesia and Tolerability in Cancer Patients: A Prospective Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(11):2898-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/11387363/pubmed\" id=\"11387363\" target=\"_blank\">",
"        11387363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ripamonti C, Groff L, Brunelli C, et al, \"Switching From Morphine to Oral Methadone in Treating Cancer Pain: What Is the Equianalgesic Dose Ratio?\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(10):3216-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/9779694/pubmed\" id=\"9779694\" target=\"_blank\">",
"        9779694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wasserman S and Yahr MD, &ldquo;Choreic Movements Induced by the Use of Methadone,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 1980, 37(11):727-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/6108101/pubmed\" id=\"6108101\" target=\"_blank\">",
"        6108101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weschules DJ and Bain KT, &ldquo;A Systematic Review of Opioid Conversion Ratios Used With Methadone for the Treatment of Pain,&rdquo;",
"      <i>",
"       Pain Med",
"      </i>",
"      , 2008, 9(5):595-612.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/18565004/pubmed\" id=\"18565004\" target=\"_blank\">",
"        18565004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wu CH and Henry JA, &ldquo;Deaths of Heroin Addicts Starting on Methadone Maintenance,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1990, 335(8686):424.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/1968162/pubmed\" id=\"1968162\" target=\"_blank\">",
"        1968162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wunsch MJ, Stanard V, and Schnoll SH, &ldquo;Treatment of Pain in Pregnancy,&rdquo;",
"      <i>",
"       Clin J Pain",
"      </i>",
"      , 2003, 19(3):148-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/12792553/pubmed\" id=\"12792553\" target=\"_blank\">",
"        12792553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/57/36761/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9623 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-ACD0464BDC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36761=[""].join("\n");
var outline_f35_57_36761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709037\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194036\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194001\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194002\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194003\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194004\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821704\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194038\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234073\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14624980\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193975\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194044\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193974\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194046\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194034\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193978\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193958\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194032\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193992\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193965\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193980\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194008\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193981\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989406\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193967\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193971\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193982\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193957\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193977\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9623|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/13/4310?source=related_link\">",
"      Methadone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/49/22296?source=related_link\">",
"      Methadone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_57_36762="Treatment of dry mouth and other non-ocular sicca symptoms in Sjgren's syndrome";
var content_f35_57_36762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36762/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36762/contributors\">",
"     Robert Fox, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36762/contributors\">",
"     Paul Creamer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36762/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/57/36762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/57/36762/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/57/36762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24155376\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren&rsquo;s syndrome (SS) is a chronic multisystem inflammatory disorder characterized by diminished lacrimal and salivary gland function. This results in the &ldquo;sicca complex,&rdquo; a combination of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). A variety of other disease manifestations may also be present, including other manifestations of exocrine gland dysfunction, such as dryness of the skin, nasal passages, and vagina; extraglandular features; and systemic symptoms, such as fever and malaise.",
"   </p>",
"   <p>",
"    SS occurs in a primary form not associated with other diseases and in a secondary form associated with other autoimmune rheumatic conditions, including rheumatoid arthritis and systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    The treatment of dry mouth, including topical therapy; the use of systemic cholinergic agents and other systemic therapies; and topical and other therapies for the management of other non-ocular sicca symptoms of SS, will be reviewed here. Other issues in SS, including the clinical manifestations; the diagnosis; the treatment of dry eyes; and the role of systemic therapy in extraglandular manifestations of SS, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=see_link\">",
"     \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=see_link\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24155383\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both local and systemic medical therapies are used in the treatment of the different manifestations of Sj&ouml;gren&rsquo;s syndrome (SS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventive therapies and attention to other conditions, medications, and environments that may exacerbate dryness complaints",
"     </li>",
"     <li>",
"      Topical therapy of dry eyes, dry mouth, other dry mucosal surfaces, and dry skin, as well as the use of systemic cholinergic agents to stimulate secretions",
"     </li>",
"     <li>",
"      Systemic antiinflammatory and immunosuppressive therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to management of patients with sicca symptoms is generally the same for primary or secondary SS and depends upon the severity of symptoms and upon the responsiveness to therapy. Patients with mild oral complaints may only require local treatment for sicca symptoms, in addition to usual medical and dental preventive care and monitoring of their condition for complications such as erythematous candidiasis.",
"   </p>",
"   <p>",
"    Most patients will benefit from multidisciplinary care. Treatment should be coordinated by a single clinician, usually a rheumatologist, in collaboration with the primary care physician and other clinicians. It is important that patients with dry mouth be seen by a dentist or an oral medicine specialist with an interest in this condition. The participation of other specialists may be required, depending upon the patient&rsquo;s particular clinical manifestations.",
"   </p>",
"   <p>",
"    Comprehensive patient education should be provided regarding SS and its management, including use of available materials from patient support groups. This is important because of the multisystem nature of the illness and because of the degree of self-care that is required. There should be particular attention to self-management strategies for tear conservation and for effective use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , to treatment of dry mouth symptoms and oral hygiene, and to recognition of symptoms requiring medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4617715\">",
"    <span class=\"h1\">",
"     TREATMENT OF DRY MOUTH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24155391\">",
"    <span class=\"h2\">",
"     Overview of management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of dry mouth due to salivary gland dysfunction aims to alleviate symptoms and to prevent complications such as dental caries, periodontal disease, halitosis, salivary gland calculi, dysphagia, and oral candidiasis. Various strategies are employed to compensate for the loss of normal salivary functions; these functions include lubricating the mucosa, helping to clear food residue that may lead to dental plaque and bacterial growth, buffering of acids that favor demineralization of teeth, and providing antimicrobial effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, stimulation of existing salivary flow and replacement of salivary secretions, along with close attention to dental care, are major aspects of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. Our treatment approach is consistent with expert opinion and is supported by the evidence reviewed in the sections below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. These interventions are discussed in detail below. Briefly, this approach includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic measures for self-care to stimulate oral secretions and to prevent oral dryness and dental caries, as well as regular preventive dental care (see",
"      <a class=\"local\" href=\"#H24155398\">",
"       'Basic measures for all patients'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"       artificial saliva",
"      </a>",
"      in patients who receive insufficient benefit from topical stimulants of salivary flow or water or who have excessive water intake (eg, resulting in nocturia) (see",
"      <a class=\"local\" href=\"#H14944513\">",
"       'Saliva substitutes'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The use of muscarinic agonists (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      ) in patients with an inadequate response to topical stimulants and to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"       artificial saliva",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H24155412\">",
"       'Topical stimulation of salivary flow'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H899135\">",
"       'Sialagogues'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Specialized interventions by a dentist with expertise in dry mouth dentistry in patients with dental caries or with very low salivary production (see",
"      <a class=\"local\" href=\"#H16911880\">",
"       'Basic dental care'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H319080\">",
"       'Dental professional care'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      A high level of suspicion for oral candidiasis, which is a common complication in patients with SS. Such patients may have mouth pain and sensitivity and may exhibit apparent resistance to treatment for symptoms of oral dryness. (See",
"      <a class=\"local\" href=\"#H4618155\">",
"       'Oral candidiasis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33949135\">",
"    <span class=\"h3\">",
"     Evaluation of response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy may be evaluated by ongoing assessment for common clinical signs of dry mouth. In addition to patient-reported dryness, these include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Difficulty with swallowing or speech due to dryness",
"     </li>",
"     <li>",
"      Absence of a pool of saliva on the floor of the mouth",
"     </li>",
"     <li>",
"      &ldquo;Lipstick sign&rdquo; (spreading of the patient&rsquo;s lipstick onto teeth)",
"     </li>",
"     <li>",
"      Sticking of a gloved finger to the mucosa",
"     </li>",
"     <li>",
"      Frequent occurrence of erythematous oral candidiasis",
"     </li>",
"     <li>",
"      Atrophic glossitis (or lack of papilla) on the tongue",
"     </li>",
"     <li>",
"      Atypical dental caries at the gingival margin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      incisal regions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24155398\">",
"    <span class=\"h2\">",
"     Basic measures for all patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following measures should be used in all patients with dry mouth due to SS, regardless of symptom severity:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention of dryness (see",
"      <a class=\"local\" href=\"#H902090\">",
"       'Prevention of dryness'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Topical stimulation of secretions (see",
"      <a class=\"local\" href=\"#H24155412\">",
"       'Topical stimulation of salivary flow'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Dental prophylaxis (see",
"      <a class=\"local\" href=\"#H16911880\">",
"       'Basic dental care'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prevention and management of potential complications of dry mouth are an important component of patient education. Patients should be instructed regarding signs and symptoms of oral candidiasis, which may mimic or exacerbate dry mouth symptoms and which requires prompt intervention. Additionally, they should be cautioned regarding the risks of cosmetic dental procedures in patients with SS and dry mouth. (See",
"    <a class=\"local\" href=\"#H4618155\">",
"     'Oral candidiasis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24155844\">",
"     'Restorative and cosmetic dentistry'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The published evidence supporting these measures is limited, largely consisting of small trials, case series, and clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1,2,6-8\">",
"     1,2,6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H902090\">",
"    <span class=\"h3\">",
"     Prevention of dryness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures against dry mouth include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance of good hydration by taking regular sips of water and by drinking sugar-free liquids, avoidance of oral irritants (eg, coffee, alcohol, and nicotine), and avoidance of acidic drinks (eg, carbonated beverages and juices)",
"     </li>",
"     <li>",
"      Avoidance of medications that may worsen oral dryness, especially those with anticholinergic side effects. These include over-the-counter cold and sleep remedies and other agents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=see_link&amp;anchor=H94900523#H94900523\">",
"       \"Treatment of dry eyes in Sj&ouml;gren's syndrome\", section on 'Avoidance of medications causing dryness'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maintenance of open nasal passages to avoid mouth breathing (see",
"      <a class=\"local\" href=\"#H13441414\">",
"       'Nasal dryness'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Avoidance of low humidity environments, such as air-conditioned stores, centrally heated houses, and airplanes, and the use of humidifiers to maintain adequate humidity, particularly at night",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Various solutions can be used to replace oral secretions, ranging from water to forms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"     artificial saliva",
"    </a>",
"    . We suggest frequent sips of water because of convenience, cost, and efficacy. The water does not have to be swallowed; it can be rinsed around the mouth and then expectorated. Although water provides temporary moisture, it does not provide the lubricating properties that are characteristic of the mucin and water mixtures that constitute normal saliva.",
"   </p>",
"   <p>",
"    Patients should be advised that excessively frequent sipping of water may actually reduce the mucus film in the mouth and may increase symptoms. If water consumption is excessive, especially in the evening, nocturia can occur, resulting in sleep disturbance that may worsen fatigue, cognitive difficulties, and pain that some patients experience.",
"   </p>",
"   <p>",
"    We advise patients to avoid acidic beverages, which may adversely affect dental enamel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/9\">",
"     9",
"    </a>",
"    ]. Examples of common beverages and their relative acidity include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cola drinks &mdash; pH 2.6",
"     </li>",
"     <li>",
"      Coffee &mdash; pH 5.0",
"     </li>",
"     <li>",
"      Tea (herbal) &mdash; pH 3.2",
"     </li>",
"     <li>",
"      Tea (black) &mdash; pH 5.7 to 7.0",
"     </li>",
"     <li>",
"      Water from tap &mdash; pH 7.0 (but flavored waters are often acidic)",
"     </li>",
"     <li>",
"      Energy drinks &mdash; usually acidic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The maintenance of a stable pH in the oral cavity is highly important. When the pH in the oral cavity is stable, there is a decrease in the amount of demineralization that takes place. The pH and buffering capacity of the parotid saliva of individuals with Sj&ouml;gren&rsquo;s syndrome are much lower than those in healthy individuals. The buffering systems responsible for the human saliva buffering capacity include bicarbonate, phosphate, and protein. Even a minor drop in pH can promote dental caries or can damage the teeth by erosion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24155412\">",
"    <span class=\"h3\">",
"     Topical stimulation of salivary flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with dry mouth should observe the basic measures described above and should use topical stimulants. Food should be chewed carefully before swallowing. Salivary flow may be stimulated in patients with residual salivary function by sucking on sugarless candies and lozenges and by using chewing gums [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Particular care must be taken not to increase the risk of dental caries. As an example, sugar-free lozenges contain significantly less sugar than &ldquo;low sugar&rdquo; mints. A clear advantage of one product over another has not been rigorously shown, and a variety of products should be tried to determine which is most acceptable and effective in a given patient.",
"   </p>",
"   <p>",
"    Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sugar-free hard candies or lozenges. Products identified as &ldquo;sugarless&rdquo; should be distinguished from those that are &ldquo;sugar-free,&rdquo; as sugarless items may contain significant amounts of fructose, thus being potentially cariogenic.",
"     </li>",
"     <li>",
"      Sugar-free chewing gums, containing various sweeteners such as aspartame, saccharin, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      , which can increase saliva production in patients with residual secretory capacity. However, there is no evidence they are more or less effective than saliva substitutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Xylitol-containing gum or candy, which may also reduce the cariogenicity of the oral bacterial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Citrus flavored sugarless tablets or oral drops, which may also contain malic acid. This acid, which is normally found in fruits such as apples or pears, stimulates salivary flow.",
"     </li>",
"     <li>",
"      Maltose lozenges, which may reduce symptoms of oral dryness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dried fruit slices, such as peaches or nectarines, which stimulate flow in many patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of topical therapies for xerostomia found 36 small trials (average size of 44 patients), with a wide range of interventions, comparisons, and outcome measures, and a resultant lack of strong evidence for efficacy of any specific topical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/7\">",
"     7",
"    </a>",
"    ]. Additionally, most of the products were not tested in patients with SS. However, there was some evidence suggesting patient preference for chewing gums, which may increase saliva production in patients with residual secretory capacity, although there was no evidence that gum was more or less effective than use of saliva substitutes. The use of these interventions is also supported by extensive clinical experience.",
"   </p>",
"   <p>",
"    Another type of salivary stimulant is a topically applied oral insert that adheres to the mucosa. It may stimulate salivary flow and may alleviate symptoms of dryness in some patients, but it has been the subject of only limited study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16911880\">",
"    <span class=\"h3\">",
"     Basic dental care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of dental caries is a major problem in patients with dry mouth. Such patients are especially prone to root and incisal caries, rather than coronal caries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2,5,13,14\">",
"     2,5,13,14",
"    </a>",
"    ]. To help avoid these complications, we suggest aggressive application of the same general principles as in individuals without dry mouth, including meticulous self-care, frequent visits to the dentist (at least every six months for patients with mild disease), and plaque control. Patients should avoid eating preprocessed &ldquo;soft&rdquo; foods, which may be high in sugar content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because these measures alone are usually insufficient, and given the multiple potential treatments with different mouthwashes, gels, pastes, and other applications, we suggest that individualized treatment should be provided by a dentist with experience or particular interest in the care of patients with dry mouth and SS. Attention to oral hygiene and self-care, along with professional dental care, are important in the prevention of dental caries and in the maintenance of oral health in patients with SS. (See",
"    <a class=\"local\" href=\"#H319080\">",
"     'Dental professional care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16911887\">",
"    <span class=\"h4\">",
"     Oral hygiene and self-care",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients do the following, under the supervision of their dentist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use dental floss after each meal and fluoride supplementation either as toothpaste or as mouth rinse daily. We advise patients to carry portable toothbrush and toothpaste to use when they will not be at home following meals. (See",
"      <a class=\"local\" href=\"#H319080\">",
"       'Dental professional care'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Use fluoride-containing toothpastes specifically designed for dry mouth. Dry mouth toothpastes lack detergents, such as sodium lauryl sulfate, which is the foaming agent in most toothpastes and which can irritate the dry mouth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/15-17\">",
"       15-17",
"      </a>",
"      ]. While infrequent, we caution patients that some of the fluoride-containing toothpastes may lead to brown discoloration of the teeth, particularly in younger patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one study, a commercially available toothpaste containing lactoperoxidase and lactoferrin was found to give improved symptomatic relief in SS patients, although no change in the microbacterial composition of the biofilm was noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use dental hygiene appliances that help remove trapped food debris. Examples of such appliances include toothbrushes with features that improve effectiveness, such as interdental brushes (for cleaning between teeth) and electric toothbrushes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16911567\">",
"    <span class=\"h2\">",
"     Insufficient response to basic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond adequately to the basic measures described above and who continue to have signs or symptoms of dry mouth, further measures include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Saliva substitutes (&ldquo;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"       artificial saliva",
"      </a>",
"      &rdquo;) (see",
"      <a class=\"local\" href=\"#H14944513\">",
"       'Saliva substitutes'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Muscarinic agonists, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H899135\">",
"       'Sialagogues'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Systemic antiinflammatory and immunosuppressive medications, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H316655\">",
"       'Systemic antiinflammatory and immunosuppressive therapy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14944513\">",
"    <span class=\"h3\">",
"     Saliva substitutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"     artificial saliva",
"    </a>",
"    in patients who do not receive sufficient symptomatic benefit from topical stimulants of salivary flow or water or who have excessive water intake (eg, resulting in nocturia). A number of artificial saliva preparations that provide more viscosity and lubrication than water are available, generally without prescription, and are dispensed as sprays, liquid rinses, gels, and lozenges. These compounds typically contain a unique mix of multiple components in each preparation, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , and electrolytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Evidence supporting the use of these products is described below. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"     \"Artificial saliva: Drug information\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14944562\">",
"     'Efficacy of artificial saliva'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several different products should be tried if a particular substitute is not acceptable, as products differ in viscosity and other characteristics, and individual patient preferences and the degree of improvement can differ between patients and between products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/19\">",
"     19",
"    </a>",
"    ]. The product should be applied to the inner lips, buccal mucosa, and hard palate. We advise patients to mix and match a variety of these agents in their daily or nightly schedule. For example, a patient may use a mouth spray before speaking to a group, an oral solution before eating to help with dysphagia, and an oral gel before bedtime. Sprays may be more difficult to use for patients with arthritis. A gel can be helpful if painful gums are a problem.",
"   </p>",
"   <p>",
"    These products can often help relieve symptoms temporarily but have not been shown in randomized trials to improve salivary flow, although observations in one study suggested improvement both in symptoms of dryness and in salivary flow with the use of an oral spray containing hydroxymethylcellulose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1,2,4,7,20\">",
"     1,2,4,7,20",
"    </a>",
"    ]. Saliva substitutes may be most useful before sleep, after waking at night with dry mouth symptoms, during telephone conversations, during social and workplace interactions, and in patients with dentures. Patients should be informed of the normal diurnal variation in saliva flow, which decreases and has altered composition at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14944562\">",
"    <span class=\"h4\">",
"     Efficacy of artificial saliva",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"     artificial saliva",
"    </a>",
"    preparations is supported by several randomized trials and by additional studies that show benefit compared with placebo in relieving symptoms of dry mouth, including burning mouth and tongue, and difficulties with chewing and swallowing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/7,19,20,22-24\">",
"     7,19,20,22-24",
"    </a>",
"    ]. Benefit was also shown by patients&rsquo; expressions of preferences for the tested product compared with placebo. However, some measures improved in one trial but not in another. A randomized crossover trial compared three different saliva preparations with different viscoelastic properties with each other and with placebo in 43 patients with SS; patients expressed a preference for artificial saliva compared with placebo or none of the choices (79 versus 5 versus 16 percent). The three artificial salivas were equally preferred, but a statistically significant reduction in symptoms was not found with any individual preparation compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other studies, a mucin-containing agent was preferred over a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    -containing agent by the study patients, but no significant difference in efficacy was identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients receiving a hydroxymethylcellulose-containing oral spray reported subjective improvement in xerostomia and showed objective improvement in swallowing (65 and 75 percent of patients, respectively) and improvement in salivary flow (from 0.12 &plusmn; 0.02 to 0.24 &plusmn; 0.09",
"    <span class=\"nowrap\">",
"     mL/minute),",
"    </span>",
"    compared with their baseline values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/20\">",
"     20",
"    </a>",
"    ]; patients treated with a mouthwash containing linseed extract salinum as a saliva substitute, with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , reported reduced symptoms of dryness and had decreased dental plaque [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small randomized trials of lubricating agents containing lactoperoxidase suggested that such agents may reduce oral discomfort and symptoms of dryness in patients with radiation xerostomia, but they have not been studied in patients with SS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H899135\">",
"    <span class=\"h3\">",
"     Sialagogues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H902366\">",
"    <span class=\"h4\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the use of a muscarinic agonist such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    in patients with salivary dysfunction and dry mouth who do not achieve sufficient salivary excretion and symptomatic relief with topical stimulants and with the use of a saliva substitute. Oral candidiasis, rather than dryness alone, should be excluded by a careful examination as a cause of worsening symptoms before initiating therapy with these agents. (See",
"    <a class=\"local\" href=\"#H900579\">",
"     'Lack of benefit from sialagogues'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4618155\">",
"     'Oral candidiasis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    have been shown in several randomized trials of each drug; these include increased salivary flow and improvement in symptoms of dry mouth in comparison with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/3,30-37\">",
"     3,30-37",
"    </a>",
"    ]. However, pilocarpine and cevimeline have not been compared directly with each other in patients with SS. (See",
"    <a class=\"local\" href=\"#H900232\">",
"     'Pilocarpine efficacy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H900463\">",
"     'Cevimeline efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These agents are most useful early in the course of SS, while the patient still has baseline saliva and greater residual excretory capacity upon stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/31,32,38-42\">",
"     31,32,38-42",
"    </a>",
"    ]. For SS patients with residual salivary gland function, it is hoped that stimulation of saliva flow with a secretagogue may aid in preventing long-term oral complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H901001\">",
"    <span class=\"h4\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    is 5 mg by mouth, four times daily, and the usual dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    is 30 mg by mouth, three times daily taken about a half hour before meals. The dose of pilocarpine or cevimeline should be increased gradually when initiating therapy, starting with one dose daily for a week, which helps to prevent a sudden onset of sweating, and taking the medication with food or using a proton pump inhibitor if needed to avoid dyspepsia and gastric bloating. We suggest a trial of at least three months&rsquo; duration if the medication is tolerated since the response is frequently delayed.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     Cevimeline",
"    </a>",
"    can be taken in a fourth dose at bedtime if needed for nocturnal dryness. Use of lower doses in patients with poor tolerance of the full dose has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2\">",
"     2",
"    </a>",
"    ]. A lower dose is prepared by dissolving the desired fraction of a 30 mg capsule&rsquo;s contents in water. The desired fraction can be taken to achieve the desired reduced dose, or the solution can be used in a &ldquo;rinse-and-spit&rdquo; regimen to minimize systemic absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increase in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    dose from 5 to 7.5 mg every six hours has been effective in some patients who have not responded to the usual dose. In some patients with unacceptable levels of side effects at the full dose, a reduced dose of 2.5 to 3.75 mg three times daily or of 5 mg twice daily may still provide benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2,36\">",
"     2,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H899651\">",
"    <span class=\"h4\">",
"     Choice of medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    , which appear equally efficacious compared with placebo, is largely determined by individual factors; these include cost to the patient, individual clinical response, convenience, and regulatory or insurance limitations on drug availability. The following factors may differentiate the drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       Cevimeline",
"      </a>",
"      , which has a longer half-life and receptor occupancy time than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      , is better tolerated by some patients and usually requires dosing only three, rather than four, times daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/31,32,43\">",
"       31,32,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       Cevimeline",
"      </a>",
"      may result in less diaphoresis or flushing than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      but causes gastrointestinal side effects more often [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/30,32-34\">",
"       30,32-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      , generally dosed four times daily, typically experience a brief spurt of saliva due to the relatively short serum half-life of this drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/32,43\">",
"       32,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some formularies require an initial trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      , which has been available longer, before approving use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      , and patients who have not responded to or who have not tolerated pilocarpine may benefit from cevimeline, as shown in trials of cevimeline including patients previously treated with pilocarpine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H900232\">",
"    <span class=\"h4\">",
"     Pilocarpine efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     Pilocarpine",
"    </a>",
"    , a muscarinic agonist that stimulates all muscarinic receptors (M1, M2, and M3), can significantly increase aqueous secretions in patients with residual salivary gland function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/33-36,44\">",
"     33-36,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to effects upon xerostomia,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    may improve symptoms of ocular dryness, although without any objective change in tear production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/36\">",
"     36",
"    </a>",
"    ]. Significant improvement in symptoms of nasal, vaginal, and skin dryness have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=see_link\">",
"     \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the largest randomized trial that demonstrated the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    , 357 patients were randomly assigned to receive either pilocarpine (5 or 2.5 mg every six hours) or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/33\">",
"     33",
"    </a>",
"    ]. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly greater proportion of patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      (5 mg), compared with those who received placebo, experienced improvement in global assessments of symptoms of both dry mouth and dry eye (61 versus 31 percent and 42 versus 26 percent, respectively).",
"     </li>",
"     <li>",
"      There was no difference in benefit found between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      2.5 mg every six hours and placebo.",
"     </li>",
"     <li>",
"      The overall withdrawal rate did not differ between the three groups (6 to 7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no published studies that have examined the long-term efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    in patients with Sj&ouml;gren&rsquo;s syndrome. A small pilot study has shown benefit using a buccal insert that releases pilocarpine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H900463\">",
"    <span class=\"h4\">",
"     Cevimeline efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     Cevimeline",
"    </a>",
"    , an effective sialagogue, is a derivative of acetylcholine with a higher affinity for muscarinic M1 and M3 receptors on the lacrimal and salivary epithelium than for receptors on cardiac tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    significantly increases salivary flow and patient &ldquo;oral quality of life\" compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/30,32,37,42,46,47\">",
"     30,32,37,42,46,47",
"    </a>",
"    ]. The efficacy of cevimeline was illustrated in a trial that randomly assigned 197 patients with either primary or secondary SS to cevimeline or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/30\">",
"     30",
"    </a>",
"    ]. The following were observed by the endpoint of the study at 12 weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients&rsquo; global assessments of dryness were improved significantly more often by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      30 mg three times daily than by doses of 15 mg three times daily or by placebo (66 versus 32 and 36 percent, respectively).",
"     </li>",
"     <li>",
"      Dry mouth symptoms were reported by patients as better significantly more often with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      (30 or 15 mg) than with placebo (66 and 45 versus 37 percent, respectively); salivary flow rate was increased significantly in patients on the 30 mg dose compared with placebo but not with the 15 mg dose.",
"     </li>",
"     <li>",
"      Dry eye symptoms were reported by patients as better significantly more often with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      (30 or 15 mg) than with placebo (39 and 31 versus 24 percent, respectively); lacrimal flow was significantly greater with the higher dose of cevimeline than with the lower dose and was significantly greater with either dose of active drug than with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drugs that inhibit cytochrome CYP2D6 and CYP3A3 also inhibit the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    . Individuals who are known to be deficient in these cytochrome isoenzymes should use cevimeline with caution. More detailed information on drug interactions and a list of medications in each group are available using Lexi-Interact, the drug interaction program, which can be accessed through a link in the &ldquo;Drug interactions&rdquo; section of the drug information topic. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     \"Cevimeline: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H899658\">",
"    <span class=\"h4\">",
"     Adverse effects and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of these medications may be limited by poor tolerance, largely due to cholinergic side effects including undesirable levels of increased or excessive sweating, increased urinary frequency, flushing, chills, rhinitis, nausea, and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/3\">",
"     3",
"    </a>",
"    ]. Other infrequent adverse effects of either medication include unintended overdoses, bradycardia, and hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following representative results were observed in randomized trials of these agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In randomized trials, common adverse events with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      have included diaphoresis, increased urinary frequency, and flushing (in 22 to 64 percent, 10 to 15 percent, and 9 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. A higher frequency of adverse events appears to be associated with the 7.5 mg dose compared with the 5 mg dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the largest randomized trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      , sweating and increased urinary frequency were both more common with pilocarpine 5 mg compared with placebo (43 versus 7 percent and 10 versus 2 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/33\">",
"       33",
"      </a>",
"      ]. No serious adverse events occurred, and only 3 percent of patients taking pilocarpine 5 mg withdrew from the study due to drug-related adverse events.",
"     </li>",
"     <li>",
"      In a large randomized trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      , the most common adverse events seen more often with the drug (30 or 15 mg dose) than with placebo were nausea (21 and 12 versus 7 percent), increased sweating (18 and 5 versus 1 percent), and diarrhea (16 and 14 versus 7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/30\">",
"       30",
"      </a>",
"      ]. Withdrawal from the study for adverse events was more common in patients on cevimeline (30 or 15 mg dose) compared with those on placebo (16 and 14 versus 4 percent, respectively). Serious adverse events were seen in less than 3 percent of patients and were not more common with cevimeline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients using these medications should be cautioned about driving at night or about performing hazardous activities in reduced lighting because of the very uncommon adverse effects of decreased visual acuity (particularly at night and in patients with central lens changes) and of impaired depth perception.",
"   </p>",
"   <p>",
"    Patients with cardiac or pulmonary disease were excluded from the clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    because of the potential for stimulation of the muscarinic M2 receptor to adversely affect the heart or lung (eg, asthmatic complications) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/43\">",
"     43",
"    </a>",
"    ]. However, clinical practice with these agents in patients with radiation xerostomia (who frequently have a long history of smoking and heart disease) has not found this to be a clinically significant problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients do not respond sufficiently enough to the muscarinic agonists to justify continued use, especially when cholinergic side effects are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H900579\">",
"    <span class=\"h4\">",
"     Lack of benefit from sialagogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inadequate symptomatic response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    may be due to oral candidiasis, which should be excluded before increasing the dose of the medication or before changing therapies. The degree of benefit from these drugs in randomized trials may have been underestimated to some extent because of the failure to require exclusion of oral candidiasis as an inclusion criterion in most trials. The examination for candidiasis should include removing of upper dentures to examine the mucosa fully and determining if signs such as angular cheilitis are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\", section on 'Xerostomia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4618155\">",
"     'Oral candidiasis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additionally, the degree of adherence to the treatment regimen, particularly with dosing four times daily, should be ascertained. Some patients may tolerate a fourth daily dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    or an increase in the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    if needed. (See",
"    <a class=\"local\" href=\"#H899135\">",
"     'Sialagogues'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316655\">",
"    <span class=\"h3\">",
"     Systemic antiinflammatory and immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally do not use systemic antiinflammatory or immunosuppressive therapies for the treatment of sicca symptoms alone, such as dry eye and mouth, although some of these agents have beneficial effects in patients with systemic and extraglandular disease and although a few have shown some efficacy for sicca symptoms, including dry mouth.",
"   </p>",
"   <p>",
"    The following agents may be beneficial for dry mouth symptoms in patients with SS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      (HCQ), which has shown mixed results in limited studies. These included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A randomized, two-year crossover trial involving 19 patients treated with HCQ or placebo that failed to demonstrate any significant change in salivary gland scintigraphy, despite some improvement in signs of inflammation including acute phase reactants and hyperglobulinemia, and that did not evaluate symptomatic outcomes or salivary flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A study of 40 patients who received HCQ (6 to 7",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      for 24 to 48 months in which the patients showed improvement in oral dryness, oral pain, and salivary flow rates (in 60, 57, and 82 percent of patients, respectively) compared with baseline values [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Several other small series reporting improvement in salivary flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/51\">",
"       51",
"      </a>",
"      ]; decreased markers of salivary inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/52\">",
"       52",
"      </a>",
"      ]; increases in unstimulated, but not in stimulated, salivary flow rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/53\">",
"       53",
"      </a>",
"      ]; or lack of significant change in flow rates in association with HCQ use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      (RTX), which has shown some evidence of benefit for dry mouth symptoms in several trials and case series, including a randomized trial involving 30 patients in which significant improvement was seen in both stimulated and unstimulated whole saliva flow rates with RTX compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/55\">",
"       55",
"      </a>",
"      ]. However, another placebo-controlled randomized trial involving 17 patients reported no significant change in the unstimulated salivary flow rate six months after administration of rituximab, although the data on glandular function in the latter study were not presented in sufficient detail to ascertain the reasons for these differences in outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other studies of rituximab have also suggested that it may improve salivary flow, with greater effects earlier in the course of disease, and that it may decrease lymphocytic salivary gland infiltration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/57-60\">",
"       57-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other agents showing mixed results, including possible objective evidence of benefit in small trials or studies, such as systemic glucocorticoids, which showed only subjective benefit in the one small randomized trial that has been performed and which showed a lack of effect on salivary flow in a long-term low-dose study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/54,61-65\">",
"       54,61-65",
"      </a>",
"      ];",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]; and epratuzumab, an anti-CD22 B cell antibody [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Several small studies and randomized trials of both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , which have failed to demonstrate benefit in patients with SS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/69-71\">",
"       69-71",
"      </a>",
"      ]. A previous study, which had reported benefit from treatment with infliximab, was subsequently retracted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/72-74\">",
"       72-74",
"      </a>",
"      ]. Other medications that have been evaluated in patients with SS without objective evidence of benefit for salivary flow or for dry mouth include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/75\">",
"       75",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/76\">",
"       76",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/77\">",
"       77",
"      </a>",
"      ], mycophenolic acid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/78\">",
"       78",
"      </a>",
"      ], etanercept [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/70,71,79\">",
"       70,71,79",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/80\">",
"       80",
"      </a>",
"      ], mizoribine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/81\">",
"       81",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H319580\">",
"    <span class=\"h3\">",
"     Investigational and other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other medications have been evaluated for use for xerostomia in SS or in other conditions, but they have significant disadvantages compared with available therapies or have not been adequately studied to justify routine clinical use for patients with SS. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25476?source=see_link\">",
"       Bethanechol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      , which are cholinergic agents available in the US for use in urinary retention and myasthenia gravis, respectively. They are not used in SS because of greater adverse effects than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      but have been evaluated in patients with radiation xerostomia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1,83,84\">",
"       1,83,84",
"      </a>",
"      ]. They have mixed muscarinic and nicotinic activity.",
"     </li>",
"     <li>",
"      Amofostine, which is an agent that may provide protection of the salivary glands during radiation therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/85\">",
"       85",
"      </a>",
"      ] but which was not as effective as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      in patients with xerostomia after radiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bromhexine (a mucolytic agent), which has also shown palliative response in radiation xerostomia and which has shown benefit in a small trial in patients with SS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/23,87\">",
"       23,87",
"      </a>",
"      ]. This agent has been withdrawn from the market in the US but is still available in several other countries.",
"     </li>",
"     <li>",
"      Topical interferon alpha, which showed some benefit in initial trials but improvement in few measures in larger well-designed trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/88-90\">",
"       88-90",
"      </a>",
"      ]. Additionally, the use of interferon alpha in patients with hepatitis C and sicca symptoms has exacerbated their dryness complaints [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/91-95\">",
"       91-95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Devices for intraoral electrical stimulation, which have been reported in small studies and randomized trials but which require further study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/96-99\">",
"       96-99",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acupuncture, which has shown mixed results in a small number of trials for xerostomia resulting from radiation therapy for cancer and which has also been studied in patients with SS with uncertain benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/100-104\">",
"       100-104",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anethole trithione, a cholagogue, which exhibited modest benefit on salivary secretion in a small randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/105\">",
"       105",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H319080\">",
"    <span class=\"h2\">",
"     Dental professional care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be seen at a minimum of every six months. More frequent visits may be necessary depending upon the severity of oral involvement, even in patients who brush regularly with toothpaste containing fluoride and who are seen regularly by their dentists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/10\">",
"     10",
"    </a>",
"    ]. Whenever possible, we suggest that patients be seen by a dentist familiar with the care of patients with SS. An alternative resource is those dentists with expertise in dry mouth who may be working collaboratively with radiation oncologists to care for patients with head and neck malignancies; such patients may experience severe sicca symptoms due to radiotherapy. Professional dental care includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent cleanings and use of minimally invasive dental techniques to treat caries and other lesions early and to prevent the need for restorative care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Guidance regarding home self-care and oral hygiene, as well as prescription, when indicated, of calcium, phosphate, and fluoride preparations, including mouthwashes, toothpastes, and gels",
"     </li>",
"     <li>",
"      Use of fluoride varnishes or topical fluoride after each professional cleaning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/106\">",
"       106",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remineralization process may benefit from provision of calcium phosphate ions through toothpaste, specialized chewing gums, or oral solutions. No long-term clinical trials have been done to test the effectiveness of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/13,107,108\">",
"     13,107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several approaches may be taken in an effort to reduce oral bacterial flora, including the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    (CHX), a topical antimicrobial agent, and of products containing baking soda, bicarbonate, or xylitol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2,109\">",
"     2,109",
"    </a>",
"    ]. In addition, CHX has an antifungal effect. It may also be used for overnight soaking of dentures, which are a potential source of bacterial and candidal infection and which should not be worn overnight.",
"   </p>",
"   <p>",
"    Polyol sweeteners, such as xylitol and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , that are not fermentable by acid-producing bacteria are of low cariogenic potential or are noncariogenic; they may prevent or limit demineralization and may promote the remineralization process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/110-114\">",
"     110-114",
"    </a>",
"    ]. Xylitol may be a useful adjunct to other anti-caries treatments but should not be considered as a substitute for fluoride or other well-established interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2,110\">",
"     2,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoride is an important element in the prevention of dental caries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/115\">",
"     115",
"    </a>",
"    ]. However, certain regions do not maintain fluoridation in the water supply; patients living in these areas are at particular risk. The increasing use of non-fluoridated bottled water in place of fluoridated tap water has also decreased fluoride exposure for some patients. Topical fluoride promotes remineralization of teeth by the development of a crystalline protective veneer at the site of demineralization and by the inhibition of bacterial metabolism and acid production. Fluoride may be applied in various forms, depending upon the severity of disease, including a mouth rinse, fluoride gels applied at home in custom fitted trays, and dental office-based application of fluoride varnish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2,116\">",
"     2,116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24155844\">",
"    <span class=\"h3\">",
"     Restorative and cosmetic dentistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SS may be at greater risk of poor outcomes or adverse effects with certain common procedures used for restorative or cosmetic dental care, including the use of dentures, implants, and brightening products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17175646\">",
"    <span class=\"h4\">",
"     Dentures and implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SS may have more difficulty wearing dentures because of the decreased moisture in the mouth. No adequately controlled clinical trials have addressed this question. In general, dentures cannot replicate the efficiency and comfort of natural teeth.",
"   </p>",
"   <p>",
"    There are scattered case reports regarding the ability of patients with SS to tolerate implants; the debilitated oral tissues and accelerated bone loss in SS patients may cause difficulty in successfully sustaining the implants. Favorable outcomes are reported in some small series, but long-term follow-up data are very limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/117\">",
"     117",
"    </a>",
"    ]. Decisions regarding use of implants in a given patient with SS should be made on an individual basis, and the limited evidence should be acknowledged. Experience with these techniques in SS patients may improve the probability of success, given the particular challenges in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17175654\">",
"    <span class=\"h4\">",
"     Brightening products",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of home products for whitening or brightening of teeth in patients with dry mouth and salivary gland dysfunction has not been studied in patients with SS. However, the use of such products should be avoided since there may be increased risk from the acidity of some over-the-counter products designed for use in patients with normal salivary flow and content.",
"   </p>",
"   <p>",
"    If professionally applied whitening processes are considered, the use of a remineralizing solution containing calcium phosphate and a fluoride treatment may be beneficial in conjunction with a bleaching treatment. Such procedures should only be performed after consultation by the patients with their dry mouth dentist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4618155\">",
"    <span class=\"h2\">",
"     Oral candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of oral candidiasis, which is a common complication of SS, is generally similar to that of other patients with oropharyngeal candidiasis but requires consideration of several SS-related factors that influence management decisions in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2,120,121\">",
"     2,120,121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link&amp;anchor=H2801192#H2801192\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\", section on 'Oral candidiasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many antifungal preparations for oral use contain sugars to improve taste, including the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      troche, which is one of the most commonly used of these medications, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      oral suspension, which contains sucrose. Thus, such agents should not be used immediately before bed without a thorough tooth brushing, or a sugar-free alternative (eg, using nystatin vaginal troches or vaginal tablets as topical oral agents) should be used instead.",
"     </li>",
"     <li>",
"      There is some concern that systemic antifungal therapy may not result in sufficient oral drug concentrations in patients with severe salivary dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with SS, the erythematous form of oropharyngeal candidiasis (sometimes termed chronic atrophic candidiasis) is prevalent and is often painful. It is most commonly seen on the tongue, on which it has an atrophic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cobblestone appearance, and as an angular cheilitis, unlike the more typical candidiasis with fluffy white plaque that is seen in immunocompromised patients without significant xerostomia. Thus, treatment for what is sometimes termed mucositis or secondary burning mouth syndrome may also be required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H10#H10\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Mucositis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24155524\">",
"    <span class=\"h1\">",
"     TREATMENT OF OTHER SICCA SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be treated for sicca symptoms other than dry eyes and dry mouth, such as nasal dryness, laryngotracheal and genitourinary symptoms, and dry skin. These problems have not been the focus of randomized trials or other studies performed in patients with SS, and their management is largely based upon the treatment of non-SS patients and upon clinical experience.",
"   </p>",
"   <p>",
"    Patients with these manifestations may also benefit from the use of muscarinic agonists, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    . Two randomized trials of pilocarpine for dry mouth and dry eyes suggested that the drug may be more effective than placebo for symptoms of nasal, skin, and vaginal dryness and for the ability to expectorate mucus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/3,33,34\">",
"     3,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13441414\">",
"    <span class=\"h2\">",
"     Nasal dryness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of nasal dryness may improve comfort and may alleviate congestion that could increase mouth breathing and that could exacerbate oral dryness. Room humidifiers may also be helpful, and saline nasal sprays should be used as needed. Gentle nasal lavage can be used to remove encrusted secretions. Additional causes of nasal blockage, such as nasal polyps and sinus infection, should be identified and treated appropriately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=see_link\">",
"     \"Etiologies of nasal symptoms: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13441422\">",
"    <span class=\"h2\">",
"     Laryngotracheal irritation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with gastroesophageal reflux (GERD) should be treated appropriately; such symptoms may mimic those of recurrent sinusitis or allergy, such as postnasal drip or frequent throat clearing with mucus, due to laryngotracheal irritation, which stimulates vagal responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/122\">",
"     122",
"    </a>",
"    ]. Inappropriate treatment with antibiotics for presumed sinusitis can increase the risk of oral candidiasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13441430\">",
"    <span class=\"h2\">",
"     Genitourinary symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with SS may experience symptoms from vaginal dryness related to SS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from estrogen deficiency or an associated disorder such as interstitial cystitis. Additionally, women with SS may be more susceptible to candida vulvovaginitis, which is discussed separately.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15386?source=see_link\">",
"     \"Candida vulvovaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17175672\">",
"    <span class=\"h3\">",
"     Vaginal dryness and dyspareunia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of preparations are available for the treatment of vaginal dryness, including topical moisturizers and lubricants; topical vaginal estrogens may benefit patients with estrogen deficiency. Patients with symptomatic vaginal dryness should be evaluated and treated in collaboration with an expert in gynecologic care. There are no randomized trials comparing the various available products in patients with SS. Patients may need to try several different products, as they differ in their viscosity, and scented products should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. In patients with dyspareunia due to vaginal dryness, use of a lubricant by the patient&rsquo;s male partner may also be of benefit. The treatments of vaginal dryness and dyspareunia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23128?source=see_link&amp;anchor=H6#H6\">",
"     \"Differential diagnosis of sexual pain in women\", section on 'Inadequate lubrication unrelated to hypoestrogenic states'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17175680\">",
"    <span class=\"h3\">",
"     Interstitial cystitis and pelvic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatments of vulvodynia (formerly vulvar vestibulitis) and interstitial cystitis are discussed in detail separately. These conditions may be exacerbated by dryness and candidiasis in patients with SS. The use of tricyclic antidepressants, sometimes employed for treatment of these conditions, should be avoided in patients with SS because of their anticholinergic side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/46/37609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16249?source=see_link\">",
"     \"Treatment of vulvodynia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13441470\">",
"    <span class=\"h2\">",
"     Dry skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of dry skin in patients with SS is similar to the management of xerosis in other medical conditions and includes the use of mild cleansers, skin moisturizers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occlusive agents; the avoidance of excessive skin washing; and the use of a humidifier. The management of xerosis and related pruritus is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=see_link&amp;anchor=H8354494#H8354494\">",
"     \"Pruritus: Overview of management\", section on 'Xerosis (dry skin)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fragranced moisturizers and heavily fragranced cleansers should be avoided, as should use of oral antihistamines, when possible, in patients with SS and pruritus because of their irritative and anticholinergic effects, respectively. We also advise patients with SS, regardless of whether it is associated with systemic lupus, to use sun blocks, sunscreens, and sun-protective clothing for additional skin protection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27142?source=see_link\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13441478\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perioral paresthesia and dry, cracking perioral skin or lips may be treated with frequent use of lip salves",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      petroleum jelly.",
"     </li>",
"     <li>",
"      Alterations in smell and taste may occur in SS patients; they may respond to treatment of occult candidiasis or replacement of zinc deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/125\">",
"       125",
"      </a>",
"      ]. Some studies and small trials in patients without SS, but with diminished taste associated with radiotherapy or other causes have also suggested that zinc supplementation might be of benefit in improving taste sensation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/57/36762/abstract/126-128\">",
"       126-128",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44212?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24155552\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with Sj&ouml;gren&rsquo;s syndrome (SS) and dry mouth should be instructed in basic measures for self-care to stimulate oral secretions and to prevent oral dryness and dental caries. These include maintaining good hydration; avoiding sucrose, carbonated beverages, juices, and water with additives; regularly sipping water; drinking sugar-free liquids; using sugar-free salivary stimulants; avoiding medications that may worsen dryness; and using a humidifier. (See",
"      <a class=\"local\" href=\"#H24155398\">",
"       'Basic measures for all patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SS should undergo regularly scheduled preventive dental care and should be cared for by a dental hygienist and dentist with experience in dry mouth care whenever possible. Oral hygiene and dental self-care should include use of dental floss after meals, fluoride either as toothpaste or mouth rinse daily, and use of toothpastes specifically designed for dry mouth. Meticulous self-care, frequent visits to the dentist, and plaque control are necessary but are not always sufficient to completely prevent caries. (See",
"      <a class=\"local\" href=\"#H16911880\">",
"       'Basic dental care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with SS who get inadequate benefit from topical stimulants of salivary flow or from sipping water, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"       artificial saliva",
"      </a>",
"      for temporary symptomatic relief as the next step in therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Several different preparations should be tried to find which is the most helpful. (See",
"      <a class=\"local\" href=\"#H14944513\">",
"       'Saliva substitutes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with SS with salivary dysfunction and dry mouth who receive inadequate benefit from topical stimulants and saliva substitutes, we suggest the use of a muscarinic agonist, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      , as the next therapeutic option (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The usual dose of pilocarpine is 5 mg by mouth, four",
"      <span class=\"nowrap\">",
"       times/day,",
"      </span>",
"      and the usual dose of cevimeline is 30 mg by mouth, three",
"      <span class=\"nowrap\">",
"       times/day",
"      </span>",
"      taken about a half hour before meals. The dose of medication should be increased gradually when initiating therapy. (See",
"      <a class=\"local\" href=\"#H899135\">",
"       'Sialagogues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally do not use glucocorticoids or other systemic antiinflammatory or immunosuppressive therapies for the treatment of sicca symptoms alone, such as dry eye and mouth, although some of these agents have beneficial effects in patients with systemic and extraglandular disease and although a few have shown some efficacy for sicca symptoms, including dry mouth. (See",
"      <a class=\"local\" href=\"#H316655\">",
"       'Systemic antiinflammatory and immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with dental caries or very low salivary production should be evaluated by a dentist with expertise in dry mouth dentistry to determine if remineralizing mouth washes, special toothpastes, fluoride applications, or other measures are required and to direct such care. (See",
"      <a class=\"local\" href=\"#H319080\">",
"       'Dental professional care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A high level of suspicion for oral candidiasis should be maintained in patients with SS, especially in patients with mouth pain, burning, increased sensitivity, diffuse or patchy mucosal erythema, or white mucosal patches or in patients with apparent resistance to treatment, for it to be recognized early and for treatment to be promptly instituted. (See",
"      <a class=\"local\" href=\"#H4618155\">",
"       'Oral candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sicca symptoms other than dry mouth may also require treatment. In addition to dry eyes, these include nasal dryness, laryngotracheal and genitourinary symptoms, and dry skin. Patients with these manifestations may benefit from various topical measures, as well as from the use of muscarinic agonists, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=see_link\">",
"       \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H24155524\">",
"       'Treatment of other sicca symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/1\">",
"      Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum 2008; 37:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/2\">",
"      Wu AJ. Optimizing dry mouth treatment for individuals with Sj&ouml;gren's syndrome. Rheum Dis Clin North Am 2008; 34:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/3\">",
"      Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sj&ouml;gren syndrome: a systematic review. JAMA 2010; 304:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/4\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Sis&oacute;-Almirall A, et al. Topical and systemic medications for the treatment of primary Sj&ouml;gren's syndrome. Nat Rev Rheumatol 2012; 8:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/5\">",
"      Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sj&ouml;gren's syndrome. Nat Clin Pract Rheumatol 2006; 2:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/6\">",
"      Fox PC, Cummins MJ, Cummins JM. A third study on the use of orally administered anhydrous crystalline maltose for relief of dry mouth in primary Sj&ouml;gren's syndrome. J Altern Complement Med 2002; 8:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/7\">",
"      Furness S, Worthington HV, Bryan G, et al. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011; :CD008934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/8\">",
"      da Silva Marques DN, da Mata AD, Patto JM, et al. Effects of gustatory stimulants of salivary secretion on salivary pH and flow in patients with Sj&ouml;gren's syndrome: a randomized controlled trial. J Oral Pathol Med 2011; 40:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/9\">",
"      Rugg-Gunn AJ, Maguire A, Gordon PH, et al. Comparison of erosion of dental enamel by four drinks using an intra-oral applicance. Caries Res 1998; 32:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/10\">",
"      Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol 2005; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/11\">",
"      Kerr AR, Corby PM, Shah SS, et al. Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc 2010; 141:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/12\">",
"      Aframian DJ, Mizrahi B, Granot I, Domb AJ. Evaluation of a mucoadhesive lipid-based bioerodable tablet compared with Biot&egrave;ne mouthwash for dry mouth relief--a pilot study. Quintessence Int 2010; 41:e36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/13\">",
"      Papas AS, Joshi A, MacDonald SL, et al. Caries prevalence in xerostomic individuals. J Can Dent Assoc 1993; 59:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/14\">",
"      Newbrun E. Current treatment modalities of oral problems of patients with Sj&ouml;gren's syndrome: caries prevention. Adv Dent Res 1996; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/15\">",
"      Fox PC, Bowman SJ, Segal B, et al. Oral involvement in primary Sj&ouml;gren syndrome. J Am Dent Assoc 2008; 139:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/16\">",
"      Jensen JL, Barkvoll P. Clinical implications of the dry mouth. Oral mucosal diseases. Ann N Y Acad Sci 1998; 842:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/17\">",
"      Ship JA, McCutcheon JA, Spivakovsky S, Kerr AR. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J Oral Rehabil 2007; 34:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/18\">",
"      Tredwin CJ, Scully C, Bagan-Sebastian JV. Drug-induced disorders of teeth. J Dent Res 2005; 84:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/19\">",
"      van der Reijden WA, van der Kwaak H, Vissink A, et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sj&ouml;gren's syndrome. Arthritis Rheum 1996; 39:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/20\">",
"      Rhodus NL, Bereuter J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sj&ouml;gren's syndrome. J Otolaryngol 2000; 29:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/21\">",
"      Hardt M, Witkowska HE, Webb S, et al. Assessing the effects of diurnal variation on the composition of human parotid saliva: quantitative analysis of native peptides using iTRAQ reagents. Anal Chem 2005; 77:4947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/22\">",
"      Alves MB, Motta AC, Messina WC, Migliari DA. Saliva substitute in xerostomic patients with primary Sj&ouml;gren's syndrome: a single-blind trial. Quintessence Int 2004; 35:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/23\">",
"      Aagaard A, Godiksen S, Teglers PT, et al. Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study. J Oral Pathol Med 1992; 21:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/24\">",
"      Alp&ouml;z E, G&uuml;neri P, Onder G, et al. The efficacy of Xialine in patients with Sj&ouml;gren's syndrome: a single-blind, cross-over study. Clin Oral Investig 2008; 12:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/25\">",
"      Visch LL, Gravenmade EJ, Schaub RM, et al. A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int J Oral Maxillofac Surg 1986; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/26\">",
"      Johansson G, Andersson G, Edwardsson S, et al. Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sj&ouml;gren's syndrome. A double-blind crossover investigation. Gerodontology 2001; 18:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/27\">",
"      Nagy K, Urban E, Fazekas O, et al. Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer. J Craniofac Surg 2007; 18:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/28\">",
"      Epstein JB, Emerton S, Le ND, Stevenson-Moore P. A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 1999; 35:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/29\">",
"      Shahdad SA, Taylor C, Barclay SC, et al. A double-blind, crossover study of Biot&egrave;ne Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 2005; 14:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/30\">",
"      Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sj&ouml;gren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002; 46:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/31\">",
"      Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sj&ouml;gren's syndrome. Clin Immunol 2001; 101:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/32\">",
"      Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sj&ouml;gren syndrome: a randomized trial. Arch Intern Med 2002; 162:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/33\">",
"      Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj&ouml;gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999; 159:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/34\">",
"      Papas AS, Sherrer YS, Charney M, et al. Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sj&ouml;gren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol 2004; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/35\">",
"      Wu CH, Hsieh SC, Lee KL, et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sj&ouml;gren's syndrome in Taiwan--a double-blind, placebo-controlled trial. J Formos Med Assoc 2006; 105:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/36\">",
"      Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sj&ouml;gren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/37\">",
"      Leung KC, McMillan AS, Wong MC, et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sj&ouml;gren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol 2008; 27:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/38\">",
"      Cevimeline (Evoxac) for dry mouth. Med Lett Drugs Ther 2000; 42:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/39\">",
"      Maeda M, Araki M, Fujisawa T, et al. A trial of cevimeline hydrochloride (Evoxac) for patients with Sjogren's syndrome and dry mouth. Nishinihon Journal of Dermatology 2004; 66:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/40\">",
"      Katelaris CH. Pilocarpine for dry mouth and dry eye in Sj&ouml;gren's syndrome. Curr Allergy Asthma Rep 2005; 5:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/41\">",
"      Nelson JD, Friedlaender M, Yeatts RP, et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sj&ouml;gren's syndrome. The MGI PHARMA Sj&ouml;gren's Syndrome Study Group. Adv Exp Med Biol 1998; 438:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/42\">",
"      Yamada H, Nakagawa Y, Wakamatsu E, et al. Efficacy prediction of cevimeline in patients with Sj&ouml;gren's syndrome. Clin Rheumatol 2007; 26:1320.",
"     </a>",
"    </li>",
"    <li>",
"     Bryne AC. Muscarinic agonists in the treatment of Sj&ouml;gren's syndrome. A literature review of pilocarpine and cevimeline. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/44\">",
"      Nusair S, Rubinow A. The use of oral pilocarpine in xerostomia and Sj&ouml;gren's syndrome. Semin Arthritis Rheum 1999; 28:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/45\">",
"      Gibson J, Halliday JA, Ewert K, Robertson S. A controlled release pilocarpine buccal insert in the treatment of Sj&ouml;gren's syndrome. Br Dent J 2007; 202:E17; discussion 404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/46\">",
"      Suzuki K, Matsumoto M, Nakashima M, et al. Effect of cevimeline on salivary components in patients with Sj&ouml;gren syndrome. Pharmacology 2005; 74:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/47\">",
"      Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sj&ouml;gren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004; 138:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/48\">",
"      Hendrickson RG, Morocco AP, Greenberg MI. Pilocarpine toxicity and the treatment of xerostomia. J Emerg Med 2004; 26:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/49\">",
"      Kruize AA, Hen&eacute; RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sj&ouml;gren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993; 52:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/50\">",
"      Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sj&ouml;gren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/51\">",
"      Rihl M, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. Rheumatology (Oxford) 2009; 48:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/52\">",
"      Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sj&ouml;gren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999; 58:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/53\">",
"      Cankaya H, Alp&ouml;z E, Karabulut G, et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sj&ouml;gren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/54\">",
"      Reksten TR, Brokstad KA, Jonsson R, et al. Implications of long-term medication of oral steroids and antimalarial drugs in primary Sj&ouml;gren's syndrome. Int Immunopharmacol 2011; 11:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/55\">",
"      Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sj&ouml;gren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/56\">",
"      Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sj&ouml;gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/57\">",
"      Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sj&ouml;gren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/58\">",
"      Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sj&ouml;gren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/59\">",
"      Ring T, Kallenbach M, Praetorius J, et al. Successful treatment of a patient with primary Sj&ouml;gren's syndrome with Rituximab. Clin Rheumatol 2006; 25:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/60\">",
"      Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/61\">",
"      Izumi M, Eguchi K, Nakamura H, et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sj&ouml;gren's syndrome. Ann Rheum Dis 1998; 57:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/62\">",
"      Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sj&ouml;gren's syndrome. Intern Med 1999; 38:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/63\">",
"      Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sj&ouml;gren's syndrome. Clin Exp Rheumatol 1993; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/64\">",
"      Pijpe J, Kalk WW, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis 2007; 66:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/65\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Sis&oacute; A, et al. High prevalence of serum metabolic alterations in primary Sj&ouml;gren's syndrome: influence on clinical and immunological expression. J Rheumatol 2007; 34:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/66\">",
"      Dalavanga YA, Detrick B, Hooks JJ, et al. Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sj&ouml;gren's syndrome. Ann Rheum Dis 1987; 46:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/67\">",
"      Drosos AA, Skopouli FN, Costopoulos JS, et al. Cyclosporin A (CyA) in primary Sj&ouml;gren's syndrome: a double blind study. Ann Rheum Dis 1986; 45:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/68\">",
"      Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sj&ouml;gren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8:R129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/69\">",
"      Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sj&ouml;gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj&ouml;gren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/70\">",
"      Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sj&ouml;gren's syndrome: a pilot study. J Rheumatol 2004; 31:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/71\">",
"      Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sj&ouml;gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/72\">",
"      Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sj&ouml;gren's syndrome: a pilot study. Arthritis Rheum 2001; 44:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/73\">",
"      Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sj&ouml;gren's syndrome: one-year followup. Arthritis Rheum 2002; 46:3301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/74\">",
"      Steinfeld SD, Demols P, Salmon I, et al. Notice of retraction of two articles (&ldquo;Infliximab in patients with primary Sjo&uml; gren&rsquo;s syndrome: a pilot study&rdquo; and &ldquo;Infliximab in patients with primary Sjo&uml; gren&rsquo;s syndrome: one-year followup&rdquo;). Arthritis Rheum 2013; 65:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/75\">",
"      Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sj&ouml;gren's syndrome. J Rheumatol 1998; 25:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/76\">",
"      Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sj&ouml;gren's syndrome. Clin Exp Rheumatol 1996; 14:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/77\">",
"      van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sj&ouml;gren's syndrome: a phase II pilot study. Ann Rheum Dis 2007; 66:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/78\">",
"      Willeke P, Schl&uuml;ter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sj&ouml;gren syndrome: a pilot trial. Arthritis Res Ther 2007; 9:R115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/79\">",
"      Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sj&ouml;gren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008; 67:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/80\">",
"      ter Borg EJ, Haanen HC, Haas FJ, et al. Treatment of primary Sj&ouml;gren's syndrome with D-penicillamine: a pilot study. Neth J Med 2002; 60:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/81\">",
"      Nakayamada S, Saito K, Umehara H, et al. Efficacy and safety of mizoribine for the treatment of Sj&ouml;gren's syndrome: a multicenter open-label clinical trial. Mod Rheumatol 2007; 17:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/82\">",
"      Pillemer SR, Leakan RA, Sankar V, et al. Prominent adverse effects of thalidomide in primary Sj&ouml;gren's syndrome. Arthritis Rheum 2004; 51:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/83\">",
"      Hegarty A, Hodgson T. Management of xerostomia and salivary hypofunction. Prog Palliat Care 2008; 16:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/84\">",
"      Visvanathan V, Nix P. Managing the patient presenting with xerostomia: a review. Int J Clin Pract 2010; 64:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/85\">",
"      Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol 1999; 175 Suppl 4:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/86\">",
"      Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006; 64:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/87\">",
"      Frost-Larsen K, Isager H, Manthorpe R. Sj&ouml;rgren's syndrome treated with bromhexine: a randomised clinical study. Br Med J 1978; 1:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/88\">",
"      Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sj&ouml;gren's syndrome. J Interferon Cytokine Res 1998; 18:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/89\">",
"      Ship JA, Fox PC, Michalek JE, et al. Treatment of primary Sj&ouml;gren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999; 19:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/90\">",
"      Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sj&ouml;gren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/91\">",
"      Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31 Suppl 1:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/92\">",
"      Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31 Suppl 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/93\">",
"      Unoki H, Moriyama A, Tabaru A, et al. Development of Sj&ouml;gren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 1996; 31:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/94\">",
"      Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/95\">",
"      Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002; 32:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/96\">",
"      Steller M, Chou L, Daniels TE. Electrical stimulation of salivary flow in patients with Sj&ouml;gren's syndrome. J Dent Res 1988; 67:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/97\">",
"      Strietzel FP, Mart&iacute;n-Granizo R, Fedele S, et al. Electrostimulating device in the management of xerostomia. Oral Dis 2007; 13:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/98\">",
"      Fedele S, Wolff A, Strietzel F, et al. Neuroelectrostimulation in treatment of hyposalivation and xerostomia in Sj&ouml;gren's syndrome: a salivary pacemaker. J Rheumatol 2008; 35:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/99\">",
"      Strietzel FP, Lafaurie GI, Mendoza GR, et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum 2011; 63:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/100\">",
"      List T, Lundeberg T, Lundstr&ouml;m I, et al. The effect of acupuncture in the treatment of patients with primary Sj&ouml;gren's syndrome. A controlled study. Acta Odontol Scand 1998; 56:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/101\">",
"      Blom M, Kopp S, Lundeberg T. Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. Arch Otolaryngol Head Neck Surg 1999; 125:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/102\">",
"      Blom M, Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 2000; 6:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/103\">",
"      Jedel E. Acupuncture in xerostomia--a systematic review. J Oral Rehabil 2005; 32:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/104\">",
"      Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013; 31:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/105\">",
"      Hamada T, Nakane T, Kimura T, et al. Treatment of xerostomia with the bile secretion-stimulating drug anethole trithione: a clinical trial. Am J Med Sci 1999; 318:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/106\">",
"      Fox RI, Stern M, Michelson P. Update in Sj&ouml;gren syndrome. Curr Opin Rheumatol 2000; 12:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/107\">",
"      Hay KD, Thomson WM. A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/108\">",
"      Hay KD, Morton RP. The efficacy of casein phosphoprotein-calcium phosphate complex (DC-CP) [Dentacal] as a mouth moistener in patients with severe xerostomia. N Z Dent J 2003; 99:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/109\">",
"      Banting DW, Papas A, Clark DC, et al. The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. Gerodontology 2000; 17:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/110\">",
"      Zero DT. Are sugar substitutes also anticariogenic? J Am Dent Assoc 2008; 139 Suppl:9S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/111\">",
"      Ly KA, Milgrom P, Rothen M. Xylitol, sweeteners, and dental caries. Pediatr Dent 2006; 28:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/112\">",
"      Ly KA, Riedy CA, Milgrom P, et al. Xylitol gummy bear snacks: a school-based randomized clinical trial. BMC Oral Health 2008; 8:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/113\">",
"      Burt BA. The use of sorbitol- and xylitol-sweetened chewing gum in caries control. J Am Dent Assoc 2006; 137:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/114\">",
"      S&ouml;derling E. Controversies around Xylitol. Eur J Dent 2009; 3:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/115\">",
"      Daniels TE, Wu AJ. Xerostomia--clinical evaluation and treatment in general practice. J Calif Dent Assoc 2000; 28:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/116\">",
"      Wu AJ. The oral component of Sj&ouml;gren's syndrome: pass the scalpel and check the water. Curr Rheumatol Rep 2003; 5:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/117\">",
"      Isidor F, Br&oslash;ndum K, Hansen HJ, et al. Outcome of treatment with implant-retained dental prostheses in patients with Sj&ouml;gren syndrome. Int J Oral Maxillofac Implants 1999; 14:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/118\">",
"      Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants 2009; 24 Suppl:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/119\">",
"      Wood MR, Vermilyea SG, Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics. A review of selected dental literature on evidence-based treatment planning for dental implants: report of the Committee on Research in Fixed Prosthodontics of the Academy of Fixed Prosthodontics. J Prosthet Dent 2004; 92:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/120\">",
"      Hernandez YL, Daniels TE. Oral candidiasis in Sj&ouml;gren's syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol 1989; 68:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/121\">",
"      Daniels TE, Fox PC. Salivary and oral components of Sj&ouml;gren's syndrome. Rheum Dis Clin North Am 1992; 18:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/122\">",
"      Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sj&ouml;gren's syndrome. Curr Rheumatol Rep 2003; 5:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/123\">",
"      Lehrer S, Bogursky E, Yemini M, et al. Gynecologic manifestations of Sj&ouml;gren's syndrome. Am J Obstet Gynecol 1994; 170:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/124\">",
"      Bell M, Askari A, Bookman A, et al. Sj&ouml;gren's syndrome: a critical review of clinical management. J Rheumatol 1999; 26:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/125\">",
"      Henkin RI, Talal N, Larson AL, Mattern CF. Abnormalities of taste and smell in Sjogren's syndrome. Ann Intern Med 1972; 76:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/126\">",
"      Yoshida S, Endo S, Tomita H. A double-blind study of the therapeutic efficacy of zinc gluconate on taste disorder. Auris Nasus Larynx 1991; 18:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/127\">",
"      Ripamonti C, Zecca E, Brunelli C, et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998; 82:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/57/36762/abstract/128\">",
"      Heyneman CA. Zinc deficiency and taste disorders. Ann Pharmacother 1996; 30:186.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14923 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-EB31556FB1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36762=[""].join("\n");
var outline_f35_57_36762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24155552\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24155376\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24155383\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4617715\">",
"      TREATMENT OF DRY MOUTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24155391\">",
"      Overview of management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33949135\">",
"      - Evaluation of response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24155398\">",
"      Basic measures for all patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H902090\">",
"      - Prevention of dryness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24155412\">",
"      - Topical stimulation of salivary flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16911880\">",
"      - Basic dental care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16911887\">",
"      Oral hygiene and self-care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16911567\">",
"      Insufficient response to basic measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14944513\">",
"      - Saliva substitutes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14944562\">",
"      Efficacy of artificial saliva",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H899135\">",
"      - Sialagogues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H902366\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H901001\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H899651\">",
"      Choice of medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H900232\">",
"      Pilocarpine efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H900463\">",
"      Cevimeline efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H899658\">",
"      Adverse effects and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H900579\">",
"      Lack of benefit from sialagogues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H316655\">",
"      - Systemic antiinflammatory and immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H319580\">",
"      - Investigational and other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H319080\">",
"      Dental professional care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24155844\">",
"      - Restorative and cosmetic dentistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17175646\">",
"      Dentures and implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17175654\">",
"      Brightening products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4618155\">",
"      Oral candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24155524\">",
"      TREATMENT OF OTHER SICCA SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13441414\">",
"      Nasal dryness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13441422\">",
"      Laryngotracheal irritation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13441430\">",
"      Genitourinary symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17175672\">",
"      - Vaginal dryness and dyspareunia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17175680\">",
"      - Interstitial cystitis and pelvic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13441470\">",
"      Dry skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13441478\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24155552\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=related_link\">",
"      Artificial saliva: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12932?source=related_link\">",
"      Cevimeline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/46/37609?source=related_link\">",
"      Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23128?source=related_link\">",
"      Differential diagnosis of sexual pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=related_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43369?source=related_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27142?source=related_link\">",
"      Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8330?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44212?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26826?source=related_link\">",
"      Treatment of dry eyes in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=related_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16249?source=related_link\">",
"      Treatment of vulvodynia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_57_36763="Adherence improvement patients";
var content_f35_57_36763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strategies to improve adherence: patient and medication-related",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Inform patient regarding side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticipate and treat side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simplify food requirements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid adverse drug interactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If possible, reduce dose frequency and number of pills.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negotiate a treatment plan that the patient understands and to which",
"he/she commits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spend time and multiple encounters to educate and explain goals of",
"therapy and need for adherence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish readiness to take medication before writing first",
"prescription.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recruit family and friends to support the treatment plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop concrete plan for specific regimen by considering meals",
"schedule, daily routines, and side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide written schedule and pictures of medications, daily or weekly",
"pillboxes, alarm clocks, pagers, or other mechanical aids for adherence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop adherence support groups or add adherence concerns to agenda of",
"other support groups.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop link with local community-based organizations regarding",
"adherence combined with educational sessions and practical strategies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider practice sessions using candy instead of pills.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://aidsinfo.nih.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36763=[""].join("\n");
var outline_f35_57_36763=null;
var title_f35_57_36764="Antibiotics for treatment of tularemia";
var content_f35_57_36764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotics for treatment of tularemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dosing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dosing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Moderate to severe illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptomycin",
"       </td>",
"       <td>",
"        10 mg/kg intramuscularly every 12 hours for 7 to 10 days.* The daily dose should not exceed 2 g.",
"       </td>",
"       <td>",
"        15 mg/kg per day intramuscularly every 12 hours for 7 to 10 days. The daily dose should not exceed 2 g.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gentamicin",
"       </td>",
"       <td>",
"        5 mg/kg intramuscularly or intravenously daily&bull;, divided every 8 hours for 7 to 10 days.",
"       </td>",
"       <td>",
"        2.5 mg/kg intramuscularly or intravenously two or three times daily for 7 to 10 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Chloramphenicol",
"        </p>",
"        <p>",
"         (for use in the setting of meningitis, in combination with an aminoglycoside)",
"        </p>",
"       </td>",
"       <td>",
"        15 to 25 mg/kg intravenously four times daily for 14 to 21 days. The daily dose should not exceed 4 g.",
"       </td>",
"       <td>",
"        15 mg/kg intravenously four times daily for 14 to 21 days. The daily dose should not exceed 4 g.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Mild illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"       </td>",
"       <td>",
"        100 mg orally twice daily for 14 days.",
"       </td>",
"       <td>",
"        <p>",
"         Should be administered to children &lt;8 years of age only if the benefits outweigh the risks.",
"        </p>",
"        <p>",
"         2&nbsp;to&nbsp;4 mg/kg per day&nbsp;orally divided in one or two doses for 14 days. The daily dose should not exceed 200 mg.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        500 to 750 mg orally twice daily for 14 days.",
"       </td>",
"       <td>",
"        Not recommended for children &lt;18 years of age.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Dosing for streptomycin and gentamicin must be adjusted according to serum concentrations for individuals with renal insufficiency, individuals over age 50, and for pediatric patients. Target serum streptomycin concentrations for IM administration are trough &lt;10 mcg/mL and peak up to 20 to 25 mcg/mL. Streptomycin is more ototoxic than other aminoglycosides and audiometric testing is warranted for situations in which serum concentration monitoring is warranted. For obese patients dosing should be determined based on adjusted weight (See \"Calculator: Ideal Body Weight (method of Devine) and Dosing Weight\").",
"    <div class=\"footnotes\">",
"     * For patients who are very ill, streptomycin 15 mg/kg every 12 hours may be administered.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      For adults with normal renal function, once-daily dosing of gentamicin is also acceptable.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      1. Dennis, DT, Inglesby, TV, Henderson, DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763.",
"      <br>",
"       2. American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2012 Report of the Committee on Infectious Diseases, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.799.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36764=[""].join("\n");
var outline_f35_57_36764=null;
var title_f35_57_36765="Rx serious VISA child";
var content_f35_57_36765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral antimicrobial regimens for definitive treatment of bacteremia and other serious vancomycin-intermediately susceptible Staphylococcus aureus infections* in children older than 30 days",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antimicrobial regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Regimens of choice",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Linezolid",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &plusmn;",
"        </p>",
"        <p>",
"         Gentamicin (or &plusmn; rifampin)",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Linezolid: &lt;12 years: 30 mg/kg per day in 3 doses; &ge;12 years: 600 mg twice per day",
"        </p>",
"        <p>",
"         Gentamicin: 3 mg/kg per day in 3 doses",
"        </p>",
"        <p>",
"         Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Daptomycin",
"         <sup>",
"          &Delta;&sect;",
"         </sup>",
"         &plusmn;",
"        </p>",
"        <p>",
"         Gentamicin (or &plusmn; rifampin)&loz;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Daptomycin: 9 mg/kg",
"         <sup>",
"          &yen;",
"         </sup>",
"         per day in 1 dose",
"        </p>",
"        <p>",
"         Gentamicin: 3 mg/kg per day in 3 doses",
"        </p>",
"        <p>",
"         Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Quinupristin-dalfopristin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &plusmn;",
"        </p>",
"        <p>",
"         Gentamicin (or &plusmn; rifampin)",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Quinupristin-dalfopristin: 22.5 mg/kg per day in 3 doses",
"        </p>",
"        <p>",
"         Gentamicin: 3 mg/kg per day in 3 doses",
"        </p>",
"        <p>",
"         Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Alternative regimens",
"       </td>",
"       <td>",
"        <p>",
"         Vancomycin +",
"        </p>",
"        <p>",
"         Linezolid",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &plusmn;",
"        </p>",
"        <p>",
"         Gentamicin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Vancomycin: 60 mg/kg per day in 4 doses; maximum daily dose 4 g",
"         <sup>",
"          ",
"         </sup>",
"        </p>",
"        <p>",
"         Linezolid: &lt;12 years: 30 mg/kg per day in 3 doses; &ge;12 years: 600 mg twice per day",
"        </p>",
"        <p>",
"         Gentamicin: 3 mg/kg per day in 3 doses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Vancomycin +",
"        </p>",
"        <p>",
"         Trimethoprim-sulfamethoxazole (TMP-SMX)",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &plusmn;",
"        </p>",
"        <p>",
"         Gentamicin (or &plusmn; rifampin)",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Vancomycin: 60 mg/kg per day in 4 doses; maximum daily dose 4 g",
"         <sup>",
"          ",
"         </sup>",
"        </p>",
"        <p>",
"         TMP-SMX: 8-12 mg/kg trimethoprim/40 to 60 mg/kg sulfamethoxazole per day in 4 doses",
"        </p>",
"        <p>",
"         Gentamicin: 3 mg/kg per day in 3 doses",
"        </p>",
"        <p>",
"         Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cilndamycin",
"        <sup>",
"         ",
"        </sup>",
"        (if strain susceptible and D-test negative)",
"       </td>",
"       <td>",
"        40 mg/kg per day in 3 to 4 doses; maximum daily dose 1.2 to 2.7 g",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * MIC &gt;4 mcg/mL and &le;16 mcg/mL.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Optimal therapy is not known; dependent on in vitro susceptibility results.",
"      <br>",
"       &Delta; Consultation with an expert in infectious diseases is suggested before use.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Gentamicin or rifampin may be added for life-threatening infections, such as endocarditis or central nervous system, although there are no data from controlled trials to indicate that combination therapy is beneficial. Consultation with an expert in infectious diseases may be warranted to determine which agent to use and duration of use.",
"        <br>",
"         &sect; Daptomycin is active in vitro against multidrug-resistant gram-positive organisms, including",
"         <em>",
"          Staphylococcus aureus",
"         </em>",
"         , but is not well studied in children. It should not be used alone for the treatment of pulmonary infections. There is no experience with daptomycin in the treatment of central nervous system infections. Daptomycin is approved by the United States Food and Drug Administration only for the treatment of complicated skin and skin-structure infections in patients &ge;18 years of age.",
"         <br>",
"          &yen; May need to increase dose to 10 to 12 mg/kg per day to reach concentrations efficacious in adults.",
"          <br>",
"           &Dagger; Goal is to achieve trough levels &gt;15 to 20 mcg/mL based on adult studies.",
"           <br>",
"            &dagger; Once bacteremia is cleared.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Staphylococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29",
"        <sup>",
"         th",
"        </sup>",
"        ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.653.",
"       </li>",
"       <li>",
"        American Academy of Pediatrics. Tables of antibacterial drugs. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29",
"        <sup>",
"         th",
"        </sup>",
"        ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.807.",
"       </li>",
"       <li>",
"        Liu C, Bayer A, Cosgrove SE, et, al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"       </li>",
"       <li>",
"        Safety and Efficacy Study of Daptomycin in Pediatric Subjects (2-17 Years) With Skin and Skin Structure Infections. Available at:",
"        <a href=\"file://clinicaltrials.gov/ct2/show/NCT00711802\">",
"         clinicaltrials.gov/ct2/show/NCT00711802",
"        </a>",
"        (Accessed on August 2, 2012).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36765=[""].join("\n");
var outline_f35_57_36765=null;
var title_f35_57_36766="Algorithm for the maintenance of sinus rhythm";
var content_f35_57_36766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Maintenance of sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation. Drugs are listed alphabetically and not in order of suggested use. The seriousness of heart disease progresses from left to right, and selection of therapy in patients with multiple conditions depends on the most serious condition present.",
"    <div class=\"footnotes\">",
"     LVH: left ventricular hypertrophy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57:223. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36766=[""].join("\n");
var outline_f35_57_36766=null;
var title_f35_57_36767="Atheroma 2D TEE";
var content_f35_57_36767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/SURG/57210/Atheroma_2D_TEE_conv.mp4?title=Atheroma+2D+TEE\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atheroma on 2D TEE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complex atherosclerotic plaque with multiple mobile components visualized in the descending thoracic aorta by 2D TEE. In the video clip to the left, the aorta is visualized first in its short axis (transversely) then in its long axis (longitudinally).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Muhamed Saric and Dr. Itzhak Kronzon.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_57_36767=[""].join("\n");
var outline_f35_57_36767=null;
